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Abstract
Pathogenic streptococci have evolved specific systems to eliminate bacterial competitors
within their biological niche. In microbial environments, niche competition is often driven
by the production of short antimicrobial peptides called bacteriocins; this provides a
mechanism by which Streptococcus pyogenes may compete for ecological stability and
establish infection. Recent findings from our laboratory have identified two novel Class IIb
bacteriocin systems – Streptococcus pyogenes bacteriocin (Spb) JK and MN in the M18
serotype S. pyogenes strain MGAS8232 – that may contribute to nasopharyngeal infection.
Here, we show that galactose and CO2 are distinct regulatory cues which induce
antimicrobial activity. Under these conditions, bacteriocin-producing strains inhibit the
growth of other Gram-positive bacteria in vitro. We also demonstrate that acute infection
in the nasopharynx of mice is dependent on the expression of at least one functional
bacteriocin system. When mice are challenged intranasally with a double-bacteriocin
knockout, the bacterial burden is dramatically reduced compared to the wild-type and single
bacteriocin mutant controls. Furthermore, we show that nasal coinfection with S. pyogenes
wild-type and DspbJKMN results in a wild-type dominant population, suggesting that
bacteriocins enhance bacterial fitness in a polymicrobial environment. Taken together,
these observations demonstrate that S. pyogenes secretes bacteriocins which contribute to
the establishment of nasopharyngeal infection.
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Chapter 1: Introduction
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1.1 Streptococcus pyogenes
Streptococcus pyogenes, also known as group A Streptococcus (GAS), is a Gram-positive
extracellular bacterial pathogen with strict human tropism. This aerotolerant anaerobe
grows in chains of varying lengths and is often identified by the unique b-hemolytic
morphology it exhibits when grown on blood agar (1). The core-genome of S. pyogenes is
composed of a single circular chromosome that is ~1.8 Mbp with a low G+C content of
~39%, and encodes genes mainly involved in pathogenicity and virulence (2). Inside the
pan-genome, there is repertoire of virulence genes that are highly variable among bacterial
strains. These differences in non-essential genes are acquired via horizontal transfer of
exogenous genetic elements; a process fundamental to streptococcal evolution (3–5). With
a highly diverse genome, S. pyogenes is able to colonize human skin and mucosal surfaces,
including the throat, vagina and rectum, but is also able to cause a wide range of diseases.
These illnesses often manifest into mild cases of pharyngitis and impetigo but may also
lead to invasive diseases such as necrotizing fasciitis and streptococcal toxic shock
syndrome during severe infection. S. pyogenes has also been implicated in the development
of post-infection sequelae, including acute rheumatic fever, rheumatic heart disease and
glomerulonephritis. The Lancefield serological classification system based on surface
carbohydrate expression has identified S. pyogenes as the only member of the group A
streptococci. However, emm typing, which involves sequencing of the hypervariable region
of the M protein gene, has emerged as the dominant method of classification, identifying
over 200 GAS serotypes to date (1, 6, 7).

1.2 Global disease burden of group A Streptococcus
S. pyogenes is the etiological agent of a broad spectrum of disease. Despite its major
contributions to human morbidity and mortality, the global importance of GAS remains
largely under-recognized. Systematic reviews over the last decade have estimated the
global burden of GAS disease using population-based analyses where possible. However,
due to unreliable disease surveillance – particularly in regions where S. pyogenes has the
greatest impact (i.e., developing countries) – the absolute burden of streptococcal diseases
has been widely under-estimated (8).
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Superficial S. pyogenes skin (impetigo and pyoderma) infections and acute pharyngitis
account for more than 111 million and 616 million cases of disease per year, respectively.
Although mild diseases caused by S. pyogenes are seemingly benign, these infections
impose considerable health and economic burdens worldwide, with the highest rate of
incidence among children 5 to 15 years of age (1, 8). These infections can be easily treated
with first-line b-lactam antibiotics (8), however, if left untreated or with penetration of the
epithelial surface, S. pyogenes may also trigger a variety of severe invasive diseases. This
includes bacteremia, necrotizing fasciitis and streptococcal toxic shock syndrome, among
other less common clinical manifestations (9).
Invasive S. pyogenes infections are often life-threatening and carry a high mortality rate
(>50%) in both the developed and developing world (1, 9). Globally, invasive diseases
affect over 18.1 million individuals, with an incidence of 1.78 million cases (8). In
developed countries, the highest burden of GAS-related mortality results from invasive
disease, despite the steady decline in incidence (9). While this may account for the greatest
number of deaths in affluent countries, ~97% of the 660,000 estimated cases of invasive
GAS infections occur in less developed countries, accounting for nearly 163,000 deaths
each year. Of the cases identified, low- to middle-income areas within Sub-Saharan Africa
and Asia, and indigenous-minority groups in the developed world, are predominately
affected by invasive streptococcal diseases. Within these regions, ~29% of all bacteremia
isolates in children are caused by GAS (8, 9).
Acute rheumatic fever and its sequelae, rheumatic heart disease, continue to be the leading
causes of GAS-associated morbidity and mortality worldwide. With an estimated 15.6
million people living with rheumatic heart disease, ~233,000 premature deaths, and another
116,000 deaths each year from additional complications, rheumatic heart disease is
recognized as a global health problem (8). Studies have identified overcrowding and
poverty as risk factors of acute rheumatic fever, with ~60% of cases leading to rheumatic
heart disease. In endemic regions such as Africa, the Pacific, Latin America, the Middle
East, Asia, and indigenous populations of Australia and New Zealand, children, young
adults and pregnant women are particularly vulnerable to acute rheumatic fever and
rheumatic heart disease. To reduce the risk of acute rheumatic fever and mitigate valve

4

damage, prophylactic antibiotic treatment for GAS pharyngitis is recognized as the primary
prevention strategy. However, if acute rheumatic fever progresses to rheumatic heart
disease, surgical intervention may be required (8, 10).
The global distribution of S. pyogenes contributes to an immense burden of human illness.
However, prevalence, incidence, and mortality of disease are unequally distributed
throughout the world. Studies suggest that disease is strongly correlated with seasonal
variability, geographic location, and socio-economic status. Therefore, developing
countries are disproportionately impacted by GAS due to poor sanitary standards and
minimal access to healthcare and resources (8), making it increasingly difficult to establish
the true burden of GAS disease. Without accurate high-quality data from low-resource
settings where the burden of disease is greatest, we are unable to design appropriate
prevention and treatment strategies to control S. pyogenes outbreaks and ultimately reduce
the global burden of streptococcal disease (8, 10).

1.3 Asymptomatic carriage
The GAS carrier state is described as having a prolonged bacterial presence that does not
appear to be causing overt signs of disease. Under these circumstances, a physical
examination – swab of the posterior pharynx – and serological testing have been used to
identify the presence of S. pyogenes. If rapid diagnostic testing and/or throat culture for S.
pyogenes are positive without the classical clinical signs and symptoms of acute pharyngitis
(i.e., sore throat, inflammation of tonsils, fever), individuals are considered asymptomatic
carriers (11, 12).
GAS primarily colonizes the naso- and oropharynx in the human host (13). However, it is
unclear whether individual genetic factors and type-specific bacterial characteristics
influence host-pathogen interactions that contribute to streptococcal colonization.
Therefore, despite what we know about S. pyogenes, the predominant and benign
asymptomatic state is poorly understood. (11, 13, 14).
Many studies suggest that carriage within the human population is dependent on a number
of factors: age-group, geography, climate, repeated environmental contact and seasonal
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trends (5). For example, a 4-year longitudinal study in Pittsburgh on school-aged children
5 to 15 years of age isolated S. pyogenes from 27% to 32% of the cohort over the course of
one school year. In this study, asymptomatic children typically carried a single emm type
that persisted between 3 to 123 weeks, and those that sporadically cleared GAS were more
likely to acquire recurrent infections with a different emm type and demonstrate new
clinical symptoms (12). A meta-analysis on the prevalence and carriage of GAS in the
United States in the past 35 years found that 37% of children under 18 years of age
presenting signs of bacterial pharyngitis were positive for S. pyogenes. However, only 12%
of children surveyed were considered asymptomatic carriers of GAS (15). In Melbourne,
Australia, one study reported GAS carriage rates between 0% to 10% for children under
18. These findings were similar to the carriage rates of healthy children surveyed in both
Croatia (6%) and Iran (11%) (16, 17), but varied greatly from a study in Victoria, Australia,
which previously described carriage rates as high as 16% due to seasonal and geographic
variability (18, 19). In a family-based study in Australia, the incidence of S. pyogenes
infection increased with household exposure to primary cases of GAS pharyngitis. It was
determined that household contacts were almost twice (43%) as likely to acquire secondary
GAS infections (20). This association had been previously noted by Schwartz et al. (21),
who reported that ~25% of household contacts of children with streptococcal pharyngitis
were asymptomatic but positive for GAS. Therefore, the carrier state of GAS is both
complex and very common among school aged-children, but despite decades of research,
the underlying molecular mechanisms contributing to this dominant state remain an
enigma.

1.4 Mechanisms of colonization and disease
1.4.1

Mechanisms of adhesion

The nasopharynx and the skin are major sites of colonization for GAS. In order to cause
infection or establish asymptomatic colonization, S. pyogenes requires strong adherence
mechanisms to subvert a variety of mechanical, chemical, and biological barriers present
in humans. Surface adhesins allow S. pyogenes to bind to specific receptors on host cells,
penetrate intact barriers, and colonize in unfavourable environments with low pH and
moisture content, and among antimicrobial compounds (i.e., defensins, lysozymes) highly
prevalent on epidermal and mucosal surfaces (1, 22). While many adhesions have been
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described in the literature, expression of streptococcal adhesions are tissue-specific.
Therefore, although S. pyogenes utilizes a multi-adhesin approach that is often functionally
redundant to colonize host cells, different surface adhesins provide selectivity for the
adherence of different streptococcal strains (1, 23).

1.4.1.1

LTA

The adhesion process for GAS is often described using a two-step process. The first step
of adhesion involves a relatively weak hydrophobic interaction mediated by lipoteichoic
acid (LTA). This glycolipid moiety is a major cell surface component of Gram-positive
bacteria that plays an important role in adhesion and biofilm formation. In this model, LTA
allows S. pyogenes to overcome electrostatic repulsion and attach to a number of cell types
including buccal epithelial cells, HEp-2 cells, and polymorphonuclear cells, lymphocytes,
and erythrocytes (24–26). To mediate adherence of S. pyogenes to the epithelial layer, LTA
binds to its cognate host-receptor, fibronectin, forming a complex with other streptococcal
surface proteins (1, 26, 27). This complex stimulates multiple high-affinity, tissue-specific
interactions formed by other adhesins, including M protein, the pili, and fibronectinbinding proteins (1, 5, 27, 28).

1.4.1.2

M protein

The M protein, encoded by the emm gene, is one of the best studied surface molecules of
S. pyogenes (27). Composed of typically four repeat regions designated A through D, this
multi-domain alpha-helical coiled-coil structure extends as hair-like projections from the
surface of the bacteria. With the conserved C-terminus region anchored to the cell wall and
the hypervariable N-termini protruding from the surface, the M protein is able to adhere to
a number of eukaryotic receptors found on skin and mucosal surfaces (23, 27, 29).
Recognized for its prominent role in immune evasion and adhesion, the M protein is
considered a major virulence factor of S. pyogenes. To subvert the innate immune response,
the streptococcal M proteins possess anti-phagocytic properties rendering the bacteria
resistant to opsonization and neutrophil recognition (1, 5). However, the molecular
mechanisms involved in adherence are less understood. Much of the evidence suggests that
different M proteins bind to particular eukaryotic cells to mediate adherence. For example,
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some of the earliest work demonstrates that the M protein is required for binding to human
buccal cells (30). Alternatively, work by Courtney and colleagues (25) has showed that
certain serotypes including M1, M5, M6, and M24 are not involved in attachment to buccal
epithelial cells, but are required for adherence to the human laryngeal epithelial cell line
HEp-2. Other studies have found that specific parental M types attached to human
pharyngeal epithelial cells in greater numbers than both buccal or tongue epithelial cells.
Compared to the parental strains, the M protein-deficient strains in this study were unable
to efficiently bind epithelial cells, demonstrating the role of M protein in throat-mediated
adherence (31).
Based on these findings, it is evident that the streptococcal M proteins attach selectively to
host receptors on specific cell types. Therefore, the role of the M protein in mediating
adherence to eukaryotic cells is dependent on the M-serotype and tissue tropism. There are
four different subfamilies of emm genes that may play a partial role in determining tissue
tropism (1, 23, 27, 28, 32, 33). The chromosomal arrangement of the emm genes are divided
into five distinct patterns denoted A to E and are distinguished by the peptidoglycanspanning domain. Strains with patterns A to C have tissue site preference for the pharynx;
whereas strains with pattern D are recovered more often from cases of impetigo. Unlike
patterns A to D, strains with pattern E are not tissue specific, and have been isolated from
both the skin and the pharynx (32).
Much of the work done on M proteins suggests that multiple membrane bound proteins
may serve as cellular receptors for the M protein ligand (1, 27). There have been reports of
streptococcal M proteins binding to: fibronectin on the surface of oropharyngeal cells (34);
membrane cofactor protein CD46 on epidermal keratinocytes (35); sialic acid-containing
receptors on mucin lining the pharyngeal epithelium (36); and fucose-containing
oligosaccharides found on cultured HEp-2 cells (37). Despite these findings, there remains
a lot of controversy over the M protein and its role in S. pyogenes adherence (27).

1.4.1.3

Pili

Gram-positive and Gram-negative bacteria are decorated with long pilus-like structures
protruding from the bacterial cell wall (38, 39). These surface appendages are encoded on
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a pathogenicity island known as the fibronectin-binding, collagen-binding, T-antigen
(FCT) region, and are described as vital structures for adherence, biofilm formation, and
virulence in group A and group B streptococci. Many studies demonstrate that the GAS
pilus mediates efficient attachment to multiple human cell types, including primary and
cultured keratinocytes, as well as epithelial cells derived from human tonsils (40); the skin
(41), and the pharynx (38). To date, there have been nine different FCT islands identified.
Although these islands are highly variable in S. pyogenes, the structural integrity of the
pilus is highly conserved across serotypes. Pilus-like appendages in S. pyogenes are
composed of polymerized backbone protein covalently attached to one or two ancillary
protein caps. These structural subunits are assembled by pili-associated sortase enzymes
which are also encoded in the FCT operon (5, 27, 38). Despite our understanding of the
structure and assembly of the pilus, the complex processes involved in pili-mediated
adherence and colonization have yet to be elucidated (38).

1.4.1.4

Hyaluronic acid capsule

S. pyogenes produces a capsule comprised of hyaluronic acid; a linear polymer of Nacetylglucosamine and glucuronic acid, that yields distinct mucoid colonies when grown
on blood agar. Encoded by the 4.2 kb has operon, the hyaluronic acid capsule is highly
conserved across most clinical isolates of GAS, except M4 and M22 serotypes, which lack
the capsular genes and in turn produce hyaluronidase. As a major component of mammalian
tissue, the hyaluronic acid polysaccharide produced by S. pyogenes is structurally identical,
and therefore, poorly immunogenic in the human host (5, 42, 43).
Hyaluronic acid capsule production varies among different strains of GAS. In S. pyogenes,
capsule biosynthesis is regulated by growth conditions and in response to changes in the
host environment (5). Testing in vitro has demonstrated that capsule production is rapidly
induced during early- to mid-exponential phase (44). These observations are further
supported in vivo. During invasive infection in the peritoneum of mice, and in pharyngeal
colonization using a non-human primate model, high levels of capsule gene expression
were induced within 1-2 h after the introduction of GAS. This suggests that the hyaluronic
acid capsule is essential during the initial stages of colonization (45). Although it is widely
believed that the capsule allows GAS to persist in the pharynx, the role of the hyaluronic
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acid capsule in mediating adherence remains controversial. Many studies have
demonstrated that GAS attachment to epithelial cells occurs through binding to the cell
surface ligand CD44 (46–48). While this may serve as a critical point of attachment to
pharyngeal and epidermal cells, there is evidence to suggest that encapsulated strains of
GAS bind the epithelium with similar (49), and in some cases, reduced efficiency to
acapsular strains (46, 48). Despite these findings, encapsulated streptococcal strains seem
to provide a greater advantage in infection models. In both murine and primate models of
pharyngeal colonization, capsule-deficient strains of GAS were unable to persist in the
pharynx, and cleared rapidly by host phagocytes when compared to the wild-type strains
(49, 50). Therefore, the structural and anti-phagocytic properties of the capsule allow S.
pyogenes to circumvent the host immune response, demonstrating a critical role for the
hyaluronic acid capsule in GAS virulence and colonization.

1.4.2

Secreted virulence factors

S. pyogenes secretes a number of extracellular proteins that play an important role in
colonization and the initiation of disease. These secreted toxins are considered virulence
factors and are responsible for a diverse range of functions essential to the success of the
pathogen. This impressive arsenal of virulence factors includes: proteinases, DNases,
complement-inhibitors, plasminogen-binding proteins, hemolysins, superantigens, and
bacteriocins, which allow S. pyogenes to facilitate invasion, resist host defence
mechanisms, and outcompete endogenous microbiota within a given biological niche (1,
28, 51). Although each of these virulence factors plays a critical role disease pathogenesis,
this chapter will review the hemolysins, superantigens, and bacteriocins secreted by S.
pyogenes during infection.

1.4.2.1

Hemolysins

S. pyogenes secretes two major extracellular toxins called the streptococcal cytolysins,
streptolysin O (SLO) and streptolysin S (SLS). These potent pore-forming toxins target a
number of eukaryotic cells (51–53), which contribute to GAS virulence through a variety
of poorly understood mechanisms (51, 54, 55). The first of these hemolysins, SLO, is an
oxygen-labile and cholesterol-dependent cytolysin capable of forming large pores in the
host cell membrane to induce apoptosis (54–56). In a pore-dependent manner (57), SLO
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enhances GAS pathogenicity through the translocation of NAD+-glycohydrolase
(NADase). This toxin, which is co-expressed with SLO, is delivered to the cytoplasm of
host cells through a process known as cytolysin-mediated translocation, where it functions
to modulate host cell signalling pathways. SLO-mediated delivery of NADase interferes
with cellular repair mechanisms and prevents acidification of the phagolysosome, thereby
blocking internalization and destruction of the invading bacterium. Murine models of GAS
infection demonstrate that in the absence of SLO, S. pyogenes is significantly impaired in
its ability to survive in macrophages. These findings suggest that together, SLO and
NADase play a critical role in enhancing intracellular survival and proliferation of GAS
(52, 58–60).
In addition to SLO, S. pyogenes produces a second hemolysin known as SLS. This oxygenstable, non-immunogenic toxin is encoded by the nine-gene sag operon, which is
remarkably similar to the genetic organization of bacteriocin-gene clusters encoded by
other bacteria (56, 61). SLS is secreted by many strains of S. pyogenes and is responsible
for the distinct b-hemolytic phenotype surrounding GAS colonies grown on blood agar.
Similar to SLO, SLS possesses a broad cytotoxic spectrum that targets erythrocytes (62,
63), leukocytes (53), and platelets (64) by the formation of a transmembrane pore that
disrupts osmotic balance, resulting in cell lysis (63). However, recent studies suggest a
more complex role for SLS in facilitating GAS pathogenesis. Flaherty et al. (65)
demonstrate that SLS is capable of manipulating host cell signalling pathways, thereby
triggering a rapid proinflammatory response that leads to programmed cell death of
epithelial cells. Other groups have reported SLS-induced apoptosis of immune cells
through caspase-dependent and independent mechanisms (65, 66). These processes
implicate SLS as a critical factor for innate immune evasion by GAS (67–69). Further
evidence suggests that SLS-deficient mutants are attenuated in their ability to induce cell
death during infection (68), and are significantly less virulent than their wild-type
counterparts in vivo (54, 65, 70).

1.4.2.2

Superantigens

Streptococcal superantigens represent a large fraction of the family of mitogenic exotoxins
that are capable of inducing an exaggerated T lymphocyte response (71, 72). These highly
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potent pyrogens are best studied in Staphylococcus aureus and S. pyogenes, but are also
present in other bacterial pathogens, including group C and G streptococci, coagulasenegative staphylococci, Mycoplasma arthritidis and Yersinia pseudotuberculosis.
Together, the streptococcal and staphylococcal superantigens comprise a group of
structurally and functionally-related toxins recognized for their key role in the pathogenesis
of toxic shock syndrome (71–76).
Superantigens have a remarkable ability to simultaneously bind host major
histocompatibility complex (MHC) II molecules on antigen presenting cells and the b-chain
variable domain (Vb) on T cell receptors of CD4+ and CD8+ T cells in a peptideindependent manner. Unlike conventional T cell activation, superantigens bind outside the
designated peptide-binding groove and are not restricted by polymorphic determinants of
MHC class II. Therefore, superantigens can bind to multiple Vb chains in the T cell
repertoire and stimulate up to 25% of an individual’s T cell population, compared to
classical peptide presentation which activates only one in 105 to 106 naïve T cells (73, 75).
Recent evidence suggests that a second signalling molecule may also be required for T cell
activation by superantigens. Induction of human inflammatory cytokine gene expression
may require direct superantigen binding to co-stimulatory molecule CD28 (77) and its coligand B7-2 (CD86) (78), which are constitutively expressed on T cells and antigen
presenting cells, respectively. As a critical component of the immune response, the
superantigen-CD28-B7-2 interaction drives a hyper-active T helper 1 (Th1) response (77,
79) characterized by the overproduction of inflammatory cytokines, including tumor
necrosis factor a (TNF-a), interleukin (IL)-1b, IL-6, IL-2, and interferon (IFN)-g (23, 73,
78, 80).
Evidence suggests that other factors may influence the T cell response to superantigens.
The most important consideration is the strength and stability of the immune complex
(superantigen-MHC-T cell interaction). Although all complex formations are able to
potently activate T lymphocytes, different superantigens have unique preference or affinity
towards different binding sites, which may affect the proliferation response. For example,
nine out of fourteen streptococcal superantigens bind the MHC II b-chain in a zincdependent manner, which is referred to as the “high-affinity” binding site. In contrast, the
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MHC class II invariant a-chain is recognized as a “generic” or “low-affinity” binding site
for streptococcal superantigens (73). Furthermore, superantigens preferentially bind to
human leukocyte antigens (HLA) class II molecules, indicating that HLA polymorphisms
may also affect the binding affinity of the immune complex. High-affinity interactions
between the superantigen, MHC, and T cell receptor are thought to enhance the potency of
the resulting inflammatory response (73, 75, 81).
Although superantigens have been implicated in the development of severe streptococcal
diseases such as necrotizing fasciitis and toxic shock syndrome (73, 79), the evolutionary
advantage of superantigens is only now beginning to be understood. Recent evidence from
our laboratory has demonstrated that these exotoxins play a critical role in the initial stages
of colonization by S. pyogenes (82, 83). Using a murine model of acute nasopharyngeal
infection adapted from Park et al. (84), we show that expression of human MHC class II
molecules HLA-DR4/DQ8 and the streptococcal pyrogenic exotoxin A (SpeA) results in a
robust infection phenotype observed in transgenic mice compared to wild-type C57BL/6
mice (82). We also demonstrated that vaccination with a toxoid SpeA molecule reduced
the bacterial burden and provided antibody-mediated protection against subsequent
nasopharyngeal challenge with wild-type S. pyogenes (82, 83). Moreover, these
immunization experiments show that in the absence of Vb-specific CD4+ and CD8+ T cells,
S. pyogenes is unable to drive the proinflammatory environment necessary for
nasopharyngeal colonization. Therefore, there is strong evidence to suggest that 1) bacterial
superantigens and host MHC II molecules are required for acute infection in the
nasopharynx (82) and 2) superantigens utilize Vb-specific T cells to remodel the
nasopharyngeal environment to establish colonization (83).

1.4.2.3

Bacteriocins

Niche competition is often driven by the secretion of potent antimicrobial toxins called
bacteriocins. Bacteriocins are ribosomally-synthesized polypeptides produced by both
Gram-positive and Gram-negative bacteria, which inhibit the growth of close genetic
relatives or non-related (broad spectrum) bacteria within an ecological niche. Due to the
diverse and abundant nature of bacteriocins, families are often grouped by their mode of
action, mechanism of secretion, structure, genetics, immunity mechanism, and microbial
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targets. In complex microbial environments such as the skin, gastrointestinal tract, and the
nasopharynx, bacteriocins are thought to be used to eliminate other bacterial species
competing for the same limited space and resources. Importantly, bacteriocin-producing
strains encode additional genes which provide protection against their own antimicrobial
peptides (85, 86).
Gram-positive bacteriocins can be classified into four distinct groups based on the
classification system first proposed by Klaenhammer (87) and illustrated in Figure 1.
Although this may be the most accepted classification scheme, only three groups are
universally acknowledged in literature. Due to the increasing body of knowledge on the
structure and chemistry of bacteriocins, and inconsistency in the parameters used for
classification, there remains some criticism of the current classification approach (88).
Despite these discrepancies, all established classes will be reviewed: (I) Lantibiotics are
small (<5 kDa) membrane-active antimicrobial peptides that derive their name from the
addition of post-translationally modified amino acids such as lanthionine and bmethyllanthionine. Depending on their molecular structure, these peptides are grouped as
linear (type A) or globular (type B) lantibiotics. (II) Class II bacteriocins are small (<10
kDa), unmodified, heat-stable toxins that permeabilize target-cell membranes through an
influx of ions. In their precursor form, class II bacteriocins contain a double-glycine Nterminal leader motif, which is a hallmark of class II secretion. This motif is cleaved by a
dedicated ATP binding cassette (ABC)-transporter to produce the active secreted form.
Class II bacteriocins can also be structurally divided into multiple subclasses, including:
type-IIa (pediocin-like peptides), -IIb (two-component peptides), and -IIc (cyclic peptides).
Other subdivisions have also been considered due to differences in peptide structure. (III)
The third class of bacteriocins, recognized as the group of large (>30 kDa) heat-labile
proteins, possess a lytic- (IIIa) or non-lytic (IIIb) mode of action. Due to their enzymatic
nature, they are sometimes referred to as bacteriolysins (85, 87, 88). Lastly, a fourth class
of bacteriocins has also been proposed (87, 89, 90). This group consists of antimicrobial
peptides containing lipid or carbohydrate moieties. For example, bacteriocins with posttranslational cysteine S-glycosylation modification have been identified in Lactobacillus
plantarum (90). However, due to difficulties in peptide purification, class IV bacteriocins
have typically been dismissed (88). To illustrate the different classes and their mode of
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Figure 1. Classification of bacteriocins produced by Gram-positive bacteria.
There are four classes of Gram-positive bacteriocins based on the original classification
system proposed by Klaenhammer (87). Class IV bacteriocins are typically omitted from
the current classification scheme (85).
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action, Figure 2 provides a summary of Gram-bacteriocin activity (91).

1.5 S. pyogenes bacteriocins
Many members of the Streptococcus genus produce bacteriocins to mediate intra- and
interspecies colonization in a given biological niche. Examples include pathogenic and
benign streptococci such as Streptococcus pneumoniae and Streptococcus salivarius that
utilize bacteriocins to eliminate bacterial competitors within the oral mucosa (92).
Although various streptococci have evolved mechanisms to compete for niche space, the
bacteriocins produced by S. pyogenes are poorly characterized in comparison.
Antimicrobial activity by GAS was first observed in 1971 by the S. pyogenes strain FF22
(93). The name, streptococcin A-FF22 (SA-FF22), was ascribed to the 26-amino acid
bacteriocin, which was later classified as a type A lantibiotic for its similarity to the
prototypical lantibiotic nisin produced by Lactococcus lactis (94). SA-FF22 is
predominately active against other streptococci, and a wide range of Gram-positive bacteria
including L. lactis, Bacillus cereus, and Bacillus subtilis (92–94). However, unlike other
linear lantibiotics, SA-FF22 possesses unique structural (i.e., different proteolytic cleavage
site) and regulatory components (i.e., two-component system [TCS]) that are essential for
bacteriocin production (95).
Streptin is class A lantibiotic originally isolated and characterized from S. pyogenes.
Although the streptin locus is highly conserved across different streptococci, only 10% of
S. pyogenes strains produce a biologically active form of streptin. There are two major
forms of streptin with comparable inhibitory and autoinducing properties. The fully
processed form of streptin, referred to as streptin 1, is a 23-amino acid peptide with a broad
activity spectrum against streptococci. The second form of the peptide – streptin 2 – has
similar antimicrobial activity, yet contains three additional amino acids (TPY) at the Nterminal region (92, 96, 97). A comparison of the biosynthetic gene clusters in nisin and
subtilin demonstrate high sequence homology to the structural gene of streptin (srtA)
among other open reading frames for streptin immunity (srtI), regulation (srtR/K), transport
(srtT), prepeptide modification (srtC/B), and self-protection (srtF/E/G). The arrangement
of the operons, however, differ considerably. While most lantibiotics encode a dedicated
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Figure 2. Mode of action of Gram-positive bacteriocins.
Bacteriocins produced by Gram-positive bacteria can be grouped into three distinct classes
based on their mode of action. Some members of class I (or lantibiotic) bacteriocins have
a dual mode of action. They typically function as pore-forming toxins, but in some cases,
they may also prevent correct cell wall synthesis. Both mechanisms involve an interaction
with lipid II molecules that leads to cell lysis. Class II (small, unmodified peptides)
bacteriocins have an amphiphilic helical structure that allows them to insert into the cell
membrane of target cells. This process disrupts the membrane potential, which also results
in cell lysis. The third class of bacteriocins, referred to as bacteriolysins, directly degrades
the cell wall of target bacteria (91).
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protease for prepeptide processing, removal of the leader sequence in streptin is dependent
on the general streptococcal cysteine protease SpeB (96).
The only non-lytic and plasmid-borne bacteriocin system identified in S. pyogenes is the
large 179-amino acid polypeptide streptococcin A-M57 (SA-M57). This class III
bacteriocin system derives its name from the unique association to one serotype-specific
lineage of S. pyogenes, M57 (98, 99). SA-M57 possesses a particularly unusual activity
spectra that targets a diverse range of non-streptococcal Gram-positive bacteria, including
Micrococcus luteus, L. lactis, Bacillus megaterium, Staphylococcus simulans, and all tested
species of Listeria. Although the exact mechanism of killing remains unclear, SA-M57
secretion is thought to occur through the Sec-dependent transport pathway (85, 99).
Recent findings from our laboratory suggest that S. pyogenes also produces two class IIb
bacteriocin systems termed the S. pyogenes bacteriocins (spb) which have not been
previously characterized. To avoid confusion between the two systems, we designated the
open reading frames of the first system as the spbM and spbN genes, and those of the second
putative system as the spbJ and spbK genes (100; unpublished data) (Figure 3). Although
the latter system has not been explored in detail, we demonstrate through recombinant
expression of the SpbM and SpbN peptides that Spb possesses broad spectrum activity
against other group A and G streptococci, and Gram-positive bacteria such as M. luteus and
L. lactis. Further analysis of the structural genes spbM and spbN reveal that these peptides
are homologous to the bacteriocin-like peptide (Blp) M and N in S. pneumoniae,
respectively (100). These peptides can be found in all sequenced strains of S. pneumoniae
and may contribute to nasopharyngeal colonization (101, 102). Similarly, most sequenced
strains of S. pyogenes contain complete sequences for spbM and spbN, suggesting that the
Spb locus provides a potential advantage during colonization (100). Since there are no prior
reports of functional two-peptide bacteriocin systems in S. pyogenes, the next section will
provide an overview of the structural and intrinsic properties common to all class IIb
bacteriocins.
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1.5.1

Class IIb bacteriocins

Class IIb bacteriocins consist of two different peptides that function together as a single
antimicrobial unit. Although the individual peptides may display low antimicrobial
properties, the production of two complementary peptides in equal amounts is required to
induce optimal activity (103, 104). The structural genes encoding the two peptides are
adjacent in the operon and found next to the immunity gene –which offers protection from
the bacteriocins in an unknown mechanism – and genes for bacteriocin export. In their
immature form, each peptide is synthesized with a double-glycine N-terminal leader
sequence ~15-30 amino acids in size. This motif is cleaved off at the C-terminal side by a
dedicated ABC-transporter, resulting in export of the mature peptides out of the cell.
Together, the two peptides – often referred to as a and b – form a transmembrane helicalhelical structure that penetrates into the hydrophobic core of target cell membranes.
Through the highly conserved GxxxG-motifs present on the peptides, the double helix
structure remains stabilized in a parallel orientation, which allows for formation of the pore
(103, 105).
Aside from their unique structural features, class IIb bacteriocins have pore-forming
abilities that differ in specificity. With few exceptions, the members of this group possess
a relatively narrow inhibitory spectrum that is limited to their own bacterial species. This
specificity is predominately determined by the N-terminal amino acid sequence of the bpeptide, and is displayed with respect to the molecules conducted across the cell membrane
(104, 106). For example, lactococcin G produced by L. lactis disrupts the membrane
potential by increasing permeability to a number of monovalent cations such as sodium,
potassium, and choline, with the exception of protons. But it appears that other two-peptide
systems, such as plantaricin E/F and plantaricin J/K produced by L. plantarum, transport
monovalent ions, including protons, efficiently across the cell membrane to induce
membrane-leakage and cell death (105).
To regulate bacteriocin expression, most two-peptide systems employ a sophisticated
intracellular communication system known as quorum-sensing. Quorum-sensing is
bacterial cell-to-cell communication that relies on changes in cell density to regulate
expression of a wide variety of genes within the cell (107). This system is usually comprised
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Figure 3. Map of sil-spb loci in the M18 serotype S. pyogenes strain MGAS8232.
Open reading frame maps of the Streptococcus invasion locus (sil) and the Streptococcus
pyogenes bacteriocin (spb) operons in S. pyogenes MGAS8232 (accession: NC_003485.1).
The spbJK locus, located downstream of the sil operon, encodes the bacteriocin structural
genes, spbJ and spbK, and an associated immunity protein, spbL, for degradation of the
bacteriocins through a putative membrane-bound metalloprotease. The spbMN locus,
located upstream of the sil operon, encodes two adjacent bacteriocin genes, spbM and spbN,
and a functional immunity protein, spbI, with a frameshift mutation.
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of three components: an intracellular response regulator (RR), a membrane-associated
histidine protein kinase (HK), and a peptide pheromone (104, 105). Peptide pheromones,
also referred to as induction peptides, are small, typically unmodified peptides that are
highly related to class IIb bacteriocins in structure. They contain the same N-terminal signal
motif that is recognized by the bacteriocin export machinery during secretion. Once the
inducing peptide reaches a threshold concentration, the bacteria respond accordingly to
collectively regulate gene expression within their environment (107). Therefore, signal
transduction is initiated when the peptide pheromone interacts with the HK. This triggers a
phosphorylation event of the RR that subsequently activates transcription of the
bacteriocins and associated genes, as well as the induction peptide (104). After a certain
amount of time, the genes are downregulated, resulting in the inactivation of quorumsensing based bacteriocin production (108).

1.6 S. pyogenes metabolism
Different sites of infection represent a nutritionally unique landscape for S. pyogenes that
differ in carbohydrate availability and abundance. To thrive in these diverse
microenvironments, S. pyogenes has adapted numerous pathways to generate energy in the
cell and maintain metabolic fitness (109). While many pathways contribute to the success
of S. pyogenes as a pathogen, this chapter will focus on carbohydrate metabolism with
respect to glucose and lactose utilization.

1.6.1

Glucose metabolism and transport

Like most bacteria, the preferred carbohydrate source for S. pyogenes is glucose. In
glucose-rich environments, S. pyogenes generates energy through the classical glycolytic
pathway known as the Ebden-Meyerhof-Parnas (EMP) pathway. This pathway consists of
twelve coupling enzymes that are activated by divalent cations such as magnesium (Mg2+)
and manganese (Mn2+). Once activated, the enzymes bind to negatively-charged, highenergy phosphorylated substrates to catabolize glucose into pyruvate. This conversion
yields immediate energy in the form of two molecules of adenosine triphosphate (ATP) and
nicotinamide adenine dinucleotide (NADH2) (109).
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While glucose may be the favoured substrate, S. pyogenes must adapt to specific nutritional
microenvironments depending on the site of infection. For example, during colonization of
the oral cavity or the skin where glucose is present in only scarce amounts, S. pyogenes
must rely on alternative substrates and metabolic pathways to generate energy for growth
and survival (109). However, in the presence of glucose, the genes responsible for
catabolizing complex carbohydrates are repressed. This conserved regulatory phenomenon,
referred to as carbohydrate catabolite repression (CCR), enables streptococci to cope with
alternating periods of carbohydrate starvation and excess glucose availability by the
differential regulation of genes (109, 110).
In S. pyogenes, CCR is regulated by the phosphoenolpyruvate (PEP)-dependent
phosphotransferase (PTS) system which catalyzes the uptake and transport of various
carbohydrate sources though phosphorylation-dependent mechanisms. The PTS is
composed of two cytoplasmic components, enzyme I (EI) and a histidine-containing
phosphoryl carrier protein (HPr), in addition to one-membrane spanning protein known as
the sugar-specific permease (EII) (109, 111, 112). Briefly, a phosphorylation cascade is
initiated when the phosphoryl donor PEP phosphorylates a conserved histidine residue in
EI. Phosphorylated EI then transfers the high-energy group to the His-15 site of HPr, which
serves as an intermediate phosphoryl donor to the EIIA and EIIB domains of the sugarspecific permease. In the final step, the phosphoryl group of EIIB is transferred to a cognate
carbohydrate molecule bound to the membrane-spanning EIIC domain of the EII complex.
The resulting phosphorylated carbohydrate is then released into the cytoplasm and
processed as glycolytic intermediate (112). In addition to PEP-mediated phosphorylation
of HPr, the phosphocarrier protein can also be phosphorylated by a HPr
kinase/phosphorylase (HPrK/P) at an alternative site. Regulation of the HPrK/P is
dependent on the concentrations of fructose 1,6-bisphosphate (FBP) and inorganic
phosphate. In general, the kinase function of HPrK/P is induced in response to high levels
of FBP. This results in phosphorylation of HPr at the Ser-46 residue, which is then able to
interact with catabolite control protein A (CcpA). Together, the CcpA-HPrSer-46 dimer
stimulates the repressor function of CCR in the presence of glucose by binding to specific
catabolite responsive elements (cre) present upstream of catabolic genes. Over time,
utilization of intracellular ATP and FBP leads to an increase in inorganic phosphate, which
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modulates phosphatase activity of the HPrK/P enzyme. Therefore, alterations in the
phosphorylated state of the PTS are dependent on the metabolic demands of the cell and
the relative concentrations of FBP and inorganic phosphate (109, 112).

1.6.2

Lactose metabolism and transport

All strains of S. pyogenes possess two lac gene clusters designated lac.1 and lac.2 that
encode components of the tagatose-6-phosphate pathway for lactose and galactose
metabolism. These operons have likely evolved from gene duplication yet serve distinctly
separate functions in S. pyogenes. The Lac.1 locus contains several truncated genes, making
it unable to catabolize the appropriate sugars. It has instead adapted a novel regulatory role
via LacD.1 as a transcriptional regulator of virulence genes, while maintaining its
enzymatic aldolase capacity. In contrast, the Lac.2 operon encodes eight full-length genes
dedicated for lactose and galactose utilization, but does not have any reported regulatory
activity (113, 114).
Lactose

and

galactose

catabolism

begin

through

PTS-mediated

uptake

and

phosphorylation. Using the lactose-specific PTS transporter encoded by the lac.2 operon,
exogenous lactose and galactose are released into the cytoplasm in the form of
phosphorylated lactose, and subsequently broken down into either energy-rich glucose or
galactose intermediates. The former molecule serves as a substrate for the canonical EMP
pathway, while the latter molecule is channeled into the tagatose-6-phophate pathway.
Following a series of catalytic events, tagatose bisphosphate aldolase (LacD.2) converts the
galactose intermediate into two three-carbon sugars, glyceraldehyde-3-phosphate (G3P)
and dihydroxyacetone phosphate (DHAP). These sugars are utilized through EMP pathway
for the formation of pyruvate (109).

1.7 Virulence gene regulators of S. pyogenes
The ability of S. pyogenes to colonize and persist in multiple tissues is dependent on its
capacity to adapt to a dynamic host environment. During infection, S. pyogenes regulates a
varied repertoire of virulence factors to cope with changes in its microenvironment. The
spatial and temporal expression of these virulence factors are controlled by a complex
network of regulators that are capable of integrating environmental cues such as nutrient
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availability, pH, osmolarity, temperature, with information on the pathogen’s own
metabolic state, to determine the appropriate response (115). This highly coordinated
response promotes nutrient acquisition and the evasion of host immune factors, which
facilitates disease progression by S. pyogenes (115, 116).
While S. pyogenes possesses 13 TCS and more than 100 stand-alone response regulators
(28), the following section will explore a few of the best characterized virulence-associated
transcriptional regulators of global gene expression.

1.7.1

CovRS

Two-component signal transduction systems in bacteria employ a common stimuliresponse coupling mechanism to sense and respond to changes in the external environment.
This system is composed of two conserved components: a membrane-bound HK and a
corresponding RR. The former consists of a sensor domain that monitors environmental
stimuli, and a cytosolic kinase domain that serves to modulate activity of the HK. When a
stimulus interacts with the sensor domain of the HK this triggers autophosphorylation of
the cytosolic domain. The phosphoryl group is then transferred from the HK to the RR,
which binds to DNA to elicit a cellular response (117).
The control of virulence (CovRS) TCS in S. pyogenes serves to regulate genes associated
with the general stress response. When cells are subjected to environmental stressors such
as elevated temperature, environmental Mg2+, low pH, LL-37, and iron starvation, CovS
signals for a change in the phosphorylation state of its cognate RR CovR (28, 118–120).
While this mechanism is thought to enhance DNA binding and transcription of downstream
effectors, it has been proposed that the non-phosphorylated state of CovR also regulates a
specific subset of genes. Therefore, CovR acts as a global transcriptional repressor of
virulence genes in both a phosphorylated and non-phosphorylated state (115).
The covRS regulon modulates transcription of ~10-15% of genes in the S. pyogenes genome
(121); many of these genes are essential for infection and evasion of the host immune
response. Although this list is not exhaustive, CovRS has been characterized as a
transcriptional repressor of virulence factors such as the hyaluronic acid capsule,
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streptolysins, DNases, streptokinase, and immunoglobulin (Ig)-degrading enzymes. While
CovR functions primarily as a global repressor of virulence genes, it also acts as a
transcriptional activator of speB cysteine protease expression (28, 115).
Spontaneous mutations that inactivate either CovR or CovS enhance the virulence of this
pathogen. In murine models of skin and soft tissue infection, mutations in the covRS genes
correlate to development of severe invasive disease by S. pyogenes. This hypervirulent
phenotype is characterized by an increase in the size and abundance of necrotic lesions,
which results from overexpression of virulence factors (i.e., capsule, C5a peptidase, DNase
Sda1) and decreased production of SpeB (28, 122–124). This renders covRS mutants highly
resistant to phagocytosis and neutrophil-mediated killing (28, 124).

1.7.2

Mga

One of the best-characterized stand-alone regulators in S. pyogenes is Mga (115). Mga is a
global response regulator that controls expression of multiple virulence genes involved in
colonization (M-protein, M-like proteins, and fibronectin- and collagen-binding proteins)
and immune evasion (C5a peptidase, complement inhibitors, and Ig-binding proteins). The
mga regulon is activated during the exponential phase of growth, and in response to
elevated CO2, increased temperature, and iron-limiting conditions (125–127). Under these
growth conditions, Mga binds to upstream promoter sites of its “core” gene targets and its
own encoding gene to upregulate transcription (128). In addition, indirect regulation by
Mga may also alter expression of other virulence gene targets, including the hyaluronic
acid capsule, SpeB, and genes involved in carbohydrate metabolism (28, 115).
All GAS isolates carry either one of two allelic variations of the mga gene which give rise
to throat (mga-1) or skin/non-specific (mga-2) infections by S. pyogenes. To adapt to such
distinct microenvironments there are strain-specific differences in the regulation of Mga
and its associated gene targets. This is considered a major driving force of tissue tropism
(129). Furthermore, recent studies demonstrate that there is a direct link between
carbohydrate utilization and Mga-dependent expression of virulence genes in S. pyogenes.
In the mga operon, there are two PTS-regulatory domains that may be phosphorylated by
the PTS. Mga appears to be phosphorylated in a carbohydrate-deficient state, suggesting
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that Mga and its associated adherence factors are preferentially downregulated to promote
tissue dissemination. However, in a carbohydrate-rich environment, mga is not
phosphorylated and able to upregulate factors that promote colonization. Therefore,
virulence factor gene expression by Mga is regulated in a temporal fashion that is coupled
to nutrient availability (28, 130).

1.7.3

CcpA

In S. pyogenes, CCR is predominately controlled by the catabolite response regulator CcpA.
CcpA serves to regulate activity of the PTS, and expression of several key virulence factors
in a carbohydrate-dependent manner. At high intracellular concentrations of glycolytic
intermediates such as FBP and inorganic phosphate, HPr interacts with CcpA to form a
dimer. In its active form, CcpA binds to cre sites located in the promoter region of catabolic
operons to repress transcription of alternative carbohydrate utilization genes [refer to
section 1.6.1 for more detail] (115).
Global transcriptional analyses of S. pyogenes have identified CcpA as an important
regulator of virulence gene expression. It controls expression of many glucose-related
virulence genes in a growth-phase dependent manner. While many of these virulence genes
(speB [encoding the cysteine protease], sagA [for streptolysin S production], and cfa
[encoding CAMP factor]) are linked to carbohydrate availability, a specific subset of CcpA
gene targets are regulated independently of glucose. This suggests that multiple catabolitesensing pathways likely contribute to the global regulation of virulence factors in S.
pyogenes (110, 131). Furthermore, it has been shown that loss of ccpA attenuates virulence
in murine models of skin ulcers (110), oropharynx colonization, and invasive
intraperitoneal infection (132).

1.7.4

LacD.1

LacD.1 was initially identified as a global regulator of virulence gene expression for its role
in negative regulation of the secreted SpeB cysteine protease. Global profiling of the S.
pyogenes transcriptome has demonstrated that LacD.1 represses SpeB expression in
response to pH levels above 6.5, high salt concentrations, and carbohydrate availability
(114). As mentioned previously, LacD.1 and its paralogous counterpart, LacD.2, possess
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aldolase activity to metabolize lactose and galactose. However, LacD.1 has a unique
regulatory role that has been adapted for virulence gene expression [refer to section 1.6.2
for more detail] (113, 114).
The mechanism by which LacD.1 regulates virulence gene expression in S. pyogenes is
poorly understood (110). Regulation appears to function independently of LacD.1 catalytic
activity but requires binding to glycolytic substrates, G3P and DHAP. Therefore, LacD.1mediated regulation is likely coupled to nutrient availability (110, 114). To validate this
hypothesis, the contribution of LacD.1 on CCR was explored with respect to glucose
utilization. Analyses have revealed that 15% of genes in S. pyogenes are altered in response
to glucose, and together, CcpA and LacD.1 may control of up to 60% of this subset in
various combinations. Regulation of affected virulence genes can occur through CcpA- and
LacD.1-independent mechanisms (for example, CcpA alone regulates lctO [encoding
lactate oxidase]), co-regulation (speB and ackA [encoding a putative arginine deaminase]),
and through pathways independent of glucose (ackA regulation by CcpA). These findings
demonstrate that differential expression of virulence genes requires the integration of
temporal and environmental cues from numerous catabolite-sensing pathways during
infection (110, 131).

1.7.5

Sil

A peptide-based quorum sensing system designated the streptococcal invasion locus (sil)
has been identified in ~18% of S. pyogenes strains. Of these strains, many harbor mutations
that render the Sil system non-functional (115, 133). However, in the M14 serotype S.
pyogenes strain JS95 isolated from patient with necrotizing fasciitis, Sil was discovered as
a key component of virulence. In this strain, Sil is associated with rapid GAS dissemination
and invasion in a murine model of human soft-tissue infection. Other findings suggest that
Sil mediates DNA transfer between different M-types (134).
The genetic organization of sil resembles two separate regulatory networks used to activate
competence (com) and bacteriocin production (blp) in S. pneumoniae (135). It contains six
genes that encode a TCS (silA/B), an ABC transporter (silD/E), and two signalling peptides
(silCR and silC) which form a novel regulatory circuit that controls the transcription of sil
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(134, 136) (refer to Figure 3). Interestingly, this signal peptide can be sensed across
different streptococci, which suggests a unique role for sil in facilitating colonization (135).
Activation of sil plays a critical role in GAS adherence and competition during infection.
Recent work has demonstrated that SLO- and SLS-mediated membrane damage triggers an
endoplasmic reticulum (ER) stress response that results in the production of asparagine.
The released asparagine is sensed by an alternative TCS that activates sil to modulate
transcription of bacteriocin production. The resulting population-wide production of
bacteriocins mediates killing of bacterial competitors and allows S. pyogenes to establish
niche dominance in the host (137, 138).

1.8 Rationale and Hypothesis
Coordination of metabolism and virulence factor expression has proven to be critical for
immune evasion and the establishment of infection by S. pyogenes. However, despite
continuous efforts to understand the dominant asymptomatic state, little is known about the
molecular processes employed by S. pyogenes to outcompete the endogenous microbiota
and stably colonize the nasopharynx.
In polymicrobial environments, intra- and interspecies competition is often driven by the
production of short antimicrobial peptides called bacteriocins; this provides a mechanism
by which S. pyogenes may compete for ecological stability in its host (86, 138). Using a
recombinase-based in vivo expression technology system developed in our laboratory by
Dr. Brent Armstrong, we previously demonstrated that spb bacteriocin expression is
upregulated upon introduction of GAS in the mouse nasopharynx (100). Therefore, we
hypothesize that the Spb bacteriocin systems contribute to the establishment of
nasopharyngeal infection. To explore this hypothesis, we sought to 1) identify the
regulatory cues and mechanisms utilized by S. pyogenes to induce bacteriocin production;
2) characterize the inhibitory spectra of the Spb bacteriocins; and 3) assess the potential
competitive advantage of the bacteriocins during nasopharyngeal infection. The work
presented here will characterize the novel Spb two-peptide bacteriocins systems and
provide greater insights into the mechanisms utilized by S. pyogenes to establish dominance
in a model of its biological niche.
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Chapter 2: Materials and Methods
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2.1 Bacterial strains, media, and growth conditions
A complete list of bacterial strains used in this study can be found in Table 1. Molecular
cloning experiments utilized the Escherichia coli XL1-Blue strain cultured at 37 °C in
Luria-Bertani (LB) broth (Thermo Fisher Scientific, Waltham, MA, USA) with agitation,
or Brain Heart Infusion (BHI; BD Biosciences, Franklin Lakes, NJ, USA) media containing
1.5% (w/v) agar (Thermo Fisher Scientific). Media was supplemented with 150 μg mL-1
erythromycin (Sigma-Aldrich Canada, Oakville, ON, Canada) as necessary. Streptococcal
strains were grown in Todd-Hewitt broth (BD Biosciences) supplemented with 1% (w/v)
Bacto Yeast Extract (BD Biosciences) (THY) and incubated at 37 °C under static
conditions. When appropriate, 1.5% agar and/or 1 μg mL-1 erythromycin were added to the
media. For bioactivity experiments utilizing galactose and glucose supplementation, filter
sterilized 10% (w/v) stock solution of sugar (Sigma-Aldrich) was added at a final
concentration of 0.5% to M17 (Oxoid, Hampshire, UK) broth (GalM17). For solid media
preparation, M17 broth was supplemented with 1.5% agar and 0.1% (w/v) calcium
carbonate (CaCO3). Indicator strains M. luteus and L. lactis spp. were grown in THY at 37
°C under aerobic and static conditions, respectively. THY agar tubes were prepared with
0.75% (w/v) agar.

2.2 DNA manipulations
2.2.1

S. pyogenes genomic DNA extraction

For total genomic DNA extractions from S. pyogenes, 1.5 mL of overnight culture was
centrifuged at 15,000 ´ g for 1 minute and washed with 0.2 mM sodium acetate. Cells were
centrifuged again and resuspended in 500 μL lysis buffer (50 mM EDTA, 0.2% SDS) with
0.02 μg RNase. Following an hour-long incubation at 70 °C, 50 μL of 5 M potassium
acetate was added to precipitate proteins in a 1-hour incubation at –20 °C. Cells were then
pelleted at 15,000 ´ g for 10 minutes. For DNA precipitation, the supernatant was
transferred to a new tube with 1 mL ice-cold 95% ethanol and incubated at –20 °C for 1
hour. Centrifugation was repeated, and the pellet was washed once in 1 mL ice-cold 70%
ethanol. The resulting DNA was air-dried, resuspended in 100 μL Qiagen Elution Buffer
(Toronto, ON, Canada), and stored at –20 °C until use.
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Table 1. Bacterial strains used in this study.
Strain/Strain No.

Description

Source

Cloning Strain:
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F′proABlaclqZΔM15 Tn10 (Tetr)]

Stratagene

M18 serotype isolated from a patient with acute
rheumatic fever (GenBank accession: NC_003485.1)

(139)

MGAS8232 DspbJK

spbJKL deletion mutant derived from MGAS8232

McCormick Lab

MGAS8232 DspbMN

spbMNI deletion mutant derived from MGAS8232

McCormick Lab

MGAS8232 DspbJKMN

MGAS8232 containing in-frame deletions of spbJKL
and spbMNI operons

McCormick Lab

Escherichia coli
XL1-Blue

Streptococcus pyogenes
MGAS8232

Indicator strains for bacteriocin typing
1
Micrococcus luteus
2
Streptococcus pyogenes M52
3
Streptococcus constallatus
4
Streptococcus uberis
5
Streptococcus pyogenes M4
6
Lactococcus lactis spp.

Burton Lab
Burton Lab
Burton Lab
Burton Lab
Burton Lab
Burton Lab

7
8

Streptococcus pyogenes M28
Streptococcus pyogenes M87

Burton Lab
Burton Lab

9

Streptococcus dysgalactiae

Burton Lab
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2.2.2

Polymerase chain reaction

All polymerase chain reaction (PCR) primers were designed using Primer3Plus
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) or New England
Biolabs Tm Calculator (https://tmcalculator.neb.com/#!/main) (Table 2) and supplied by
Sigma-Aldrich. Reactions utilized Phusion High-Fidelity DNA polymerase (0.7 µL /100
µL reaction) and 1 ´ High-Fidelity buffer (Thermo Fisher Scientific), 2 mM magnesium
chloride (MgCl2; Thermo Fisher Scientific), and a 3 mM deoxyribonucleotide triphosphate
(dNTP) mixture (Roche, Basel, Switzerland). Forward and reverse primers were added at
a final concentration of 1 µM, and 1 µL template DNA was added per 100 µL total reaction
volume. All reactions were performed in the MJ Mini or MJ Research PTC-200 Thermal
Cyclers (Bio-Rad Laboratories, Hercules, CA, USA) using the following gene
amplification conditions: 98 °C for 5 minutes to preheat the thermocycler; 98 °C for 30
seconds for initial denaturation; 30 seconds at the calculated melting temperature (Tm) to
anneal primers; 36 cycles of gene amplification at 72 °C (extension time: 30 seconds per 1
kb); and a final 7-minute extension step at 72 °C. The thermocycler was held at 4 °C to
indicate completed PCR reactions.

2.2.3

DNA visualization

DNA was visualized on 1% (w/v) agarose (Thermo Fisher Scientific) in 1 ´ TAE (40 mM
Tris-acetate, 1 mM EDTA) buffer. DNA samples were mixed with loading dye buffer (40%
[v/v] glycerol, 0.25% [w/v] bromophenol blue [International Biotechnologies, New Haven,
CT, USA]) in a 5:1 ratio and loaded into pre-cast wells in the gel, along with a standard 1
kb DNA molecular ladder (Invitrogen, Carlsbad, CA, USA). The PowerPac 200
Electrophoresis Power Supply and Chamber (Bio-Rad) was used to run the gel at 100 V for
1 hour. Agarose gels were stained with 0.05% (v/v) ethidium bromide in TAE for 15
minutes and visualized under ultraviolet light (Gel Doc; Bio-Rad Laboratories).

2.2.4

Plasmid isolation from E. coli

Plasmid DNA was isolated from an overnight culture of E. coli using the QIAprep Spin
Miniprep Kit (Qiagen) following the manufacturer’s instructions. All plasmids used in this
study can be found in Table 3.
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Table 2. Primers used in this study.
Plasmid

Primer Sequence (5¢® 3¢)a

Primers for generating deletion constructs
spbJK up XhoI for
GCG CTCGAG AAACTCATTAAGCCATTCTTT
spbJK up BamHI rev
GCG GGATCC TGTATTCATAACGAATATCTCCT
spbJK down BamHI for
GCG GGATCC TGGTTTATAAATTAGGACATATTTAAG
spbJK down XbaI rev
GCG TCTAGA TCAAATTGAGCATGACGAAG
spbMN up PstI for
GCG CTGCAG TCATCTTAGTGACTTTTACTGTCGG
spbMN up SalI rev
GCG GTCGAC AAGAACAGTATCCTGGTTTCAAAA
spbMN down SalI for
GCG GTCGAC CCTCACTAAATATATAAATGACTATCTATCACTG
spbMN down BamHI rev
GCG GGATCC TAGAATCACTGCAGAAATAATAACAATACC
covR up KpnI for
CGC GGTACC AGTTGGTTGAAGACAATCTGGTATT
covR up SalI rev
CGC GTCGAC TTTCTTTGTCATTTATACCAACCCTT
covR down SalI for
CGC GTCGAC ATTCGTGAGAAATAAGTCATAT
covR down BamHI rev
CGC GGATCC GATACTGATCTTCGATATGG
mga up PstI for
CGC CTGCAG AGCTAATGTTGGTGTAAATTGACTGA
mga up SalI rev
CGC GTCGAC ACTTACATGCATTAACTTCATGTCCT
mga down SalI for
CGC GTCGAC GCAACATCATCATAGGATTTCAGA
mga down BamHI rev
CGC GGATCC ACTCCGTTGTTCTAACTGAT
ccpA up KpnI for
CGC GGTACC GTTTCCTTGTGTTTGTGGTGAAC
ccpA up SalI rev
CGC GTCGAC TCCTTTCTATTTGAAAATGACGCTTTC
ccpA down SalI for
CGC GTCGAC ACTAAGTAACTGTGACTTATGAGCAC
ccpA down PstI rev
CGC CTGCAG GTAGCGACGAAAAGCTGC
sil up BamHI for
CGC GGATCC GTAGTTTTTTTGAAAAAAACATTTC
sil up SalI rev
CGC GTCGAC GACAAAAATATTCATTTTAACCTTTA
sil down KpnI for
sil down SalI rev
silDE up KpnI for
silDE up SalI rev

CGC GGTACC CGTTTCCTCCACTTATACTA
CGC GTCGAC ATAGGATATCATTTGTAAAAGAC
CGC GGTACC CGTTTCCTCCACTTATACTA
CGC GTCGAC ATAGGATATCATTTGTAAAAGAC

silDE down SalI for
silDE down BamHI rev

CGC GTCGAC AGTTTTAATTAAATATAATAAAATTC
CGC GGATCC TGGTAAACAGATATTAATTGTT

rgg up KpnI for
rgg up SalI rev

CGC GGTACC CATGATACGTTGGCTTTGTCTA
CGC GTCGAC TTCTTTTTCCATTTTTCCCACTTT

rgg down SalI for
rgg down BamHI rev

CGC GTCGAC GCAGATTTATGAGTTGCTTTCTATC
CGC GGATCC CTTGGTAAACCAAGGTCGAA

Primers for generating the complement plasmids
PgyrA XmaI for
GCG CCCGGG GCACCATCACCGACCAAGATTA
PgyrA KpnI rev
GCG GGTACC CATTTAAGGAATGCTCCTTTTCTAGTCAA
spbMNI comp KpnI for
GCG GGTACC ATGGAGATAAAGAAACTGGAAACATTTC
spbMNI comp BamHI rev
GCG GGATCC AAAAAAAGCACCGACTCGGTGCCACTTTTTCAA
terminator SalI
GTTGATAA GTCGAC TTAGTGAGGCCAGATAATATTTGTAGC
Primers for sequencing and screening
M13 for
GTAAAACGACGGCCAG

36

M13 rev
spbJKL integration for
spbJKL integration rev
spbMNI integration for
spbMNI integration rev

GTCATAGCTGTTTCCTG
CTCATCATCTGTTGTAGGATATAGG
GTTTGGCTTCAAGAAGACC
GAGATCGCTGTTTAAAAATAAGAGG
CTTGATACCATGTGAGCACTTCT

Primers for qRT-PCR analysis
gyrA RT for
GGTTCGTATGGCTCAGTGGT
gyrA RT rev
TTCTCTTTCGCTTCCATCGT
speC RT for
TTTGAGCAGGCGTAATTCCT
speC RT rev
TTCAACGACACACACATTAAAC
spbJ RT for
GAAATTATGGATGAGGCC
spbJ RT rev
TTACCACCAACAAGTCG
spbK RT for
GGAACAATTTGAAGTGATG
spbK RT rev
CCATTACACGCATTAGGT
spbM RT for
GGAGATAAAGAAACTGGAAA
spbM RT rev
CCCAAAGAGTAATAGCTGTT
spbN RT for
GACAACAATGAAGGAATTAAC
spbN RT rev
GTATATCCCAAATATGCTCC
a Restriction endonuclease sites are underlined in the primer sequence.
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Table 3. Plasmids used in this study.
Plasmid
pG+host5
pG+host5::DspbJK
pG+host5::DspbMN
pG+host5::DspbJKMN
pG+host5::DcovR
pG+host5::Dmga
pG+host5::DccpA
pG+host5::Dsil
pG+host5::DsilDE
pG+host5::Drgg
pTRKL2
pTRKL2::PgyrA
pTRKL2::PgyrA::spbMNI
a

Descriptiona
Temperature-sensitive Gram-positive/E. coli shuttle
vector; Ermr
spbJK deletion plasmid inserted into the genome of
MGAS8232
spbMN deletion plasmid inserted into the genome of
MGAS8232
Plasmid used to delete spbJK and spbMN operons in
MGAS8232
Plasmid used to delete covR gene in MGAS8232
Plasmid used to delete mga gene in MGAS8232
Plasmid used to delete ccpA gene in MGAS8232
Plasmid used to delete the sil operon in MGAS8232
Plasmid used to delete the silD and silE genes
encoding an ABC-transporter in MGAS8232
Plasmid used to delete rgg gene in MGAS8232
Low-copy Gram-positive/E. coli shuttle vector; Ermr
pTRKL2 plasmid carrying the constitutive gyrA
promoter
pTRKL2 containing spbMNI driven by the gyrA
promoter and rrnB terminator fused to spbI

Abbreviations: Ermr, erythromycin resistance.

Source
(140)
McCormick Lab
McCormick Lab
McCormick Lab
This study
This study
This study
This study
This study
This study
(141)
McCormick Lab
McCormick Lab
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2.2.5

Preparation of E. coli competent cells

For preparation of rubidium chloride competent cells, an overnight culture of E. coli XL1Blue was subcultured 1:100 in PSI broth (0.5% [w/v] Bacto Yeast Extract [BD
Biosciences], 2% [w/v] Bacto Tryptone [BD Biosciences], 0.5% [w/v] magnesium
sulphate, pH 7.6) and grown aerobically at 37 °C to an optical density at 600 nm (OD600)
of 0.5. The bacteria were incubated on ice for 15 minutes followed by 5 minutes of
centrifugation (5,000 ´ g) at 4 °C. The pellet was resuspended in 0.4 ´ the original volume
of TfbI buffer (100 mM rubidium chloride, 50 mM manganese chloride, 30 mM potassium
acetate, 10 mM calcium chloride, 15% [v/v] glycerol, pH 5.8) and chilled on ice for another
15 minutes. Cells were centrifuged and resuspended in 0.04 ´ the original volume of TfbII
buffer (75 mM calcium chloride, 10 mM rubidium chloride, 10 mM 3-(N-morpholino)
propanesulfonic acid, 15% [v/v] glycerol, pH 6.5) and stored in 200 µL aliquots at -80 °C.

2.2.6

E. coli transformation

Recombinant plasmids were transformed into competent E. coli by heat-shock. Briefly,
competent cells were thawed, 10 µL of the ligation reaction was added, and cells were
incubated on ice for 30 minutes. Cells were shocked at 42 °C for 45 seconds and placed on
ice for an additional 2 minutes. Cells were transferred to a new tube with 900 µL LB and
incubated at 37 °C with aeration for 1 hour. The bacteria were plated on BHI agar with
appropriate antibiotics and incubated overnight at 37 °C. Clones were verified via
sequencing by the Sequencing Facility at the John P. Robarts Research Institute at Western
University, London, ON, Canada.

2.2.7

Preparation of S. pyogenes competent cells

An overnight culture of S. pyogenes was used to inoculate THY broth supplemented with
0.6% glycine (1:50). Hyaluronidase (1 mg mL-1) was added within two hours of incubation
and bacteria were grown to an OD600 of ~0.3. Cells were pelleted at 7,000 ´ g for 5 minutes,
washed once in 0.4 ´ the original volume with ice-cold 15% [v/v] glycerol, and resuspended
again in 0.04 ´ 15% [v/v] glycerol. Competent cells were stored in 200 µL aliquots at -80
°C until use.
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2.2.8

S. pyogenes electroporation

Correct plasmids were introduced into S. pyogenes by electroporation. Briefly, 2 μg of
DNA were thoroughly mixed with electrocompetent cells thawed to room temperature.
Cells were transferred to a 2 mm electroporation cuvette and pulsed exponentially at 2500
V and 600 W using the Bio-Rad GenePulser. Bacteria were then transferred to 10 mL THY
and recovered at 37 °C. After 3 hours, cells were pelleted at 6,000 ´ g and resuspended in
1 mL THY. Cells were plated on THY and incubated at 37 °C until colonies were visible.
When appropriate, erythromycin was added to solid media.

2.2.9

Construction of deletion mutants

References to genomic loci are based on the genome of S. pyogenes MGAS8232, an M18
clinical isolate associated with acute rheumatic fever (139). In-frame deletion mutants in
the genes encoding SpbJKL, SpbMNI, CovR, CcpA, Mga, Rgg, SilDE, and Sil were
generated in the Gram-positive/E. coli shuttle vector, pG+host5 (140) (Table 3). Using the
appropriate PCR primers (refer to Table 2), two ~500 bp fragments flanking the upstream
and downstream regions of the gene of interest were amplified from MGAS8232. PCR
products, as well as pG+host5, were digested using restriction endonucleases (New England
Biolabs, Ipswich, MA, USA) and purified using the QIAquick PCR Purification Kit
(Qiagen). Purified products were ligated together using T4 DNA Ligase (New England
Biolabs). Ligations were performed with an insert:vector molar ratio of 5:1 and incubated
overnight at room temperature. The resulting constructs were transformed into competent
E. coli XL1-Blue and verified by DNA sequencing.
Using the pG+host5 system which contains a temperature-sensitive origin of DNA
replication and an erythromycin selection marker, target wild-type genes were replaced
with a mutant allele via homologous recombination (Figure 4). This process has been
previously described in detail (140). Briefly, knockout constructs were electroporated into
S. pyogenes MGAS8232 and grown at 30 °C on THY agar supplemented with
erythromycin. Visible colonies were cultured in THY broth with erythromycin at 30 °C for
up to four days. Bacteria was streak plated onto THY with erythromycin and incubated at
40 °C. At this temperature, the plasmid is unable to replicate, and cells that have integrated
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Figure 4. Molecular cloning strategy for generating gene deletions in the S. pyogenes
MGAS8232 genome.
In-frame genetic deletions were generated in S. pyogenes MGAS8232 using the pG+host5
plasmid, which contains a temperature-sensitive origin of DNA replication and an
erythromycin resistance marker. Briefly, bacteria were grown in THY supplemented with
erythromycin at 30 °C to enable plasmid replication. At the non-permissive temperature
(40 °C), plasmid-integrated colonies (i.e., single-crossover clones that have undergone the
first recombination event) were screened. Selected clones were next cultured in THY
without erythromycin at 30 °C to stimulate the double cross-over event that leads to plasmid
excision. Correct clones were verified by loss of erythromycin resistance and PCR.

41

42

the plasmid remain resistant to erythromycin. To verify the first integration event into the
chromosome, genomic DNA was extracted from individual colonies grown at 40 °C and
plasmid integration was confirmed by PCR. Correct clones were then subcultured 1:100 in
THY broth without antibiotics at 30 °C. Bacteria were streaked daily on THY to isolate
individual colonies. Patching of individual colonies on THY with and without
erythromycin was used to identify clones that lost resistance to erythromycin, indicating
that the plasmid was cured. Sensitive clones were next verified by PCR and DNA
sequencing.

2.2.10

Complementation of spb mutants

For complementation of the spb in-frame deletions, DNA fragments containing the spbMNI
genes were amplified from MGAS8232 without its native promoter element and inserted
under control of the gyrA promoter in pTRKL2 as previously described (141). The resulting
plasmid was introduced into MGAS8232 DspbJKMN for constitutive expression of the
spbMN operon.

2.3 Bioactivity assays
Bacteriocin-typing or “P-typing” is a method used to characterize bacteria based on their
production of bacteriocins or sensitivity to a range of different bacteriocins. Patterns of
inhibitory activity are determined using two fundamental assays commonly referred to as
the simultaneous- and deferred-antagonism tests. These assays, which are often performed
on solid media, are used to identify indicator organisms that are sensitive to bacteriocin
production (142). In particular, typing of streptococci utilizes a set of nine indicators (I1-I9)
(143), which are listed in Table 1.
The simultaneous antagonism assay produces an environment where test strains (i.e.,
bacteriocin-producing strains) and selected indicators are in direct competition (142).
Briefly, overnight cultures of MGAS8232 wild-type, DspbJK, DspbMN and DspbJKMN
were spotted (10 µL) on 0.5% GalM17 agar buffered with 0.1% CaCO3 and incubated
overnight at 37 °C under atmospheric and elevated (5%) levels of CO2. A THY agar tube
inoculated 1:100 with an overnight culture of the target indicator strain was poured on the
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pre-inoculated plate and incubated for 24–48 hours at 37 °C to form a confluent bacterial
lawn. However, bacteriocins are also diffusible inhibitors that are released during the initial
stages of bacterial growth (142). Therefore, to investigate diffusion of inhibitory substances
into the media, the deferred antagonism assay was utilized. Test strains were streaked from
one end of the plate to the other using a sterile cotton swab and incubated under similar
conditions above. Following overnight incubation, bacterial growth was mechanically
removed, and all remaining viable cells were exposed to chloroform. An overnight culture
of the target indicator was streaked perpendicular to the test strain, and bacteria were
incubated at 37 °C for 24 hours.

2.4 Growth curves
S. pyogenes MGAS8232 wild-type and isogenic mutant strains were grown from frozen
stocks and subcultured twice (1:100 dilution) in THY broth at 37 °C. On day 3, 6 mL
overnight culture was used to inoculate 100 mL pre-warmed THY to early log-exponential
phase. Bacterial samples were adjusted to an OD600 of 0.02, and loaded in triplicate, along
with blank controls, in a sterile 96-well plate. Bacteria were grown under appropriate
conditions and OD600 measurements were recorded every 15 minutes for 18 hours using the
Synergy HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA).

2.5 In vivo experiments
2.5.1

Ethics Statement

All animal experiments were conducted in accordance with the Canadian Council on
Animal Care Guide to the Care and Use of Experimental Animals. The animal protocol
(2017-024) was approved by the Animal Use Subcommittee at Western University
(London, ON, Canada) (Appendix 1).

2.5.2

Murine nasopharyngeal infection model

Mice were bred and housed in the West Valley Barrier Facility at Western University. All
experiments were performed using transgenic C57BL/6 (B6) mice expressing the major
histocompatibility complex (MHC) II human leukocyte antigen (HLA)-DQ8 donated from
the Kotb Laboratory (144, 145). As previously described (82, 83, 146), HLA-DQ8 mice 9–
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13 weeks of age were intranasally inoculated with ~108 CFU of S. pyogenes grown to early
exponential phase (OD600 ~0.2–0.4) and resuspended in Hanks’ Balanced Saline Solution
(HBSS; Life Technologies, Carlsbad, CA, USA). Mice were anaesthetized with Forane
(isoflurane, USP; Baxter International, Deerfield, IL, USA) and nasally infected with a 7.5
µL dose of bacteria per nostril. At 48 hours post-infection, mice were sacrificed and their
complete nasal turbinates (cNTs), including the nasal-associated lymphoid tissue (NALT),
nasal turbines (NT), and maxillary sinuses (MS), were extracted (Figure 5). The cNTs were
homogenized in TE (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) buffer, serially diluted, and
plated on Trypticase Soy Agar (TSA) supplemented with 5% sheep’s blood (BD
Biosciences) for bacterial enumeration. Counts less than 25 CFU per 100 µL of cNT were
considered below the theoretical limit of detection (147).

2.5.3

Time-course of S. pyogenes infection

Mice were inoculated intranasally with 15 µL HBSS-vehicle or wild-type S. pyogenes
MGAS8232 on day 0 as previously described (see above). To examine whether the length
of infection affected microbial abundance in the nasopharynx, mice were anesthetized and
sacrificed at 24-hour time points for up to 96 hours post-infection. Mice infected with the
vehicle control were sacrificed of day 0. All cNTs were processed on TSA, BHI, and TSA
with 5% sheep’s blood for bacterial enumeration, and stabilized in RNAprotect Cell
Reagent (Qiagen) for storage at -80 °C.

2.1.1 Nasopharyngeal competition experiments
To determine whether Spb production outcompetes spb-deficient strains of streptococci, S.
pyogenes MGAS8232 and the DspbJK, DspbMN, and DspbJKMN mutants were grown to
early exponential phase and prepared individually for intranasal inoculation. An equal
volume of wild-type MGAS8232 was mixed with each of the isogenic mutants for a
colonization ratio of 1:1. These strains were then diluted 1:2 with HBSS to the appropriate
inoculum dose. Control mice were infected with either 108 CFU MGAS8232 wild-type or
the respective mutant strain. Mice were euthanized 48 hours post-inoculation and cNTs
were collected and homogenized in 500 µL TE buffer, serially diluted in HBSS, and plated
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Figure 5. Isolation of murine complete nasal turbinates.
(A) A cross-section view of a mouse head to visualize the nasal passage. (B) Front view of
the nasal passage, including the maxillary sinuses (MS), nasal turbines (NT) and the nasalassociated lymphoid tissue (NALT) [Image modified (148)]. The collective tissue
environment is known as the complete nasal turbinates (cNT).
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for bacterial enumeration on TSA with 5% sheep’s blood. In some experiments, mice were
administered 2 mg L-1 neomycin sulphate in their drinking water two days prior and
throughout the length of infection to reduce variability in the nasal microbiota. Other
experiments utilized clean water to examine the effects of background nasal microbiota on
colonization efficiency. cNTs collected from non-antibiotic treated mice were stabilized in
RNAprotect Cell Reagent and stored at -80 °C for future analysis.

2.1.2

Complementation of spbMNI

The expression plasmid pTRKL2, containing spbMNI under control of the gyrA promoter
(pTRKL2::PgyrA::spbMNI),

was

transferred

to

MGAS8232

DspbJKMN

by

electroporation. To determine whether plasmid-based complementation of one functional
bacteriocin system was able to restore antimicrobial activity, mice were inoculated with
~108 CFU of S. pyogenes grown to early exponential phase. Nasal inoculations were
performed as described above.

2.1.3

Co-colonization ratio

Hemolytic colonies recovered from control-treated mice and mice inoculated with
competing bacterial strains were patched on GalM17 agar supplemented with 0.1% CaCO3
and incubated overnight at 37 °C in 5% CO2. Colonies with inhibitory activity, or lack
thereof, against M. luteus were quantified by clearance zones or overgrowth, respectively.

2.2 S. pyogenes RNA extraction
S. pyogenes cells, from frozen or fresh overnight cultures (OD600 ~0.2–0.8), were incubated
with 1 mL RNAprotect Cell Reagent for 5 minutes at room temperature. The cells were
centrifuged for 10 minutes at 15,000 ´ g and resuspended in 500 µL Tris-EDTA Glucose
(10 mM Tris, 2 mM EDTA, 25% glucose) buffer with 5 µL of 20 mg mL-1 lysozyme and
5 µL of 10 U µL-1 mutanolysin. Cells were incubated in 37 °C water bath for 1 hour.
Following centrifugation at 21,000 ´ g, cells were resuspended in 500 µL lysis buffer (50
mM EDTA, 0.2% SDS) with 10 µL 10 mg mL-1 proteinase K and incubated at 65 °C for 2
hours. RNA was isolated using the RNeasy Kit (Qiagen) according to the manufacturer’s
instructions.
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2.3 Quantitative reverse transcriptase PCR
RNA was used to generate cDNA using SuperScript II Reverse Transcriptase (RT) and
Random Primers purchased from Invitrogen Life Technologies. Sequence-specific primers
were designed for spb antimicrobial genes with an amplicon length of ~200 bp. All gene
samples, including the gyrA housekeeping gene and speC positive control, were first
amplified from wild-type MGAS8232 genomic DNA and quantified using the NanoDrop
One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific). Purified
products were adjusted to a starting concentration of 5 ng µL-1 (100) and serially diluted to
10-8 in Qiagen Elution Buffer. The quantitative reverse transcriptase (qRT)-PCR reactions
were performed using iQ SYBR Green Supermix (Bio-Rad) according to manufacturer’s
recommendations. All reactions were performed using the appropriate primers (refer to
Table 2) and template, with an additional no template and minus RT control. Samples were
run on a Corbett Life Sciences Rotor-Gene 6000 (Sydney, Australia) using the following
gene amplification conditions: 95 °C for 5 minutes, denaturation for 10 seconds at 95 °C,
10 seconds at 60 °C to anneal primers, and a 20 second extension at 72 °C (´ 45 cycles).
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3.1 Confirmation of spb deletion mutants
In-frame deletions of the spbJK and spbMN operons in S. pyogenes MGAS8232 were
previously designed and generated by Dr. Armstrong of the McCormick laboratory (Table
3; Figure 6A). Deletion mutants were validated using PCR amplification with primers in
the flanking regions of the deleted regions. This analysis demonstrated that compared to
wild-type, the MGAS8232 DspbJK strain was found to have a 1854 bp deletion in the spbJK
region, the DspbMN strain featured a 1049 bp deletion, and the double mutant was shown
to include both these deletions (Figure 6B). Growth in THY media was compared to ensure
that the mutations had no detrimental effects on the growth rate of S. pyogenes. MGAS8232
DspbJK, DspbMN, and DspbJKMN mutants were found to have no major growth difference
when compared to wild-type (Figure 6C).

3.2 In vitro expression of spb genes is induced by CO2 and
galactose
Virulence factor gene expression in S. pyogenes is coregulated by multiple regulatory loci
in a growth phase-dependent manner (110, 131). With regard to bacteriocins produced by
other Gram-positive bacteria, patterns of gene expression have been linked directly to the
growth cycle and changes in environmental conditions (149, 150). For example, it has been
shown that environmental cues such as pH (150, 151), temperature (152, 153), and the
accumulation of specific quorum-sensing molecules (149) are able stimulate bacteriocin
synthesis. To determine the optimal conditions required to induce Spb production by S.
pyogenes, wild-type and isogenic mutant strains of MGAS8232 were grown on M17 media
supplemented with various carbohydrate sources and cultivated under different growth
parameters; antimicrobial activity was detected by growth inhibition of indicator strains.
Here, we show that growth in the presence of 5% CO2 and 0.5% galactose are distinct
regulatory cues that appear to activate spb expression in vitro. Under these conditions, S.
pyogenes strains encoding both or one of the spb gene clusters produced an antimicrobial
compound that was active against M. luteus. To confirm that the spb operons were
responsible for the antimicrobial activity of MGAS8232, the double-bacteriocin knockout
strain was also screened for activity. As anticipated, the DspbJKMN mutant showed no
detectable antimicrobial activity. Furthermore, M. luteus formed a confluent bacterial lawn
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Figure 6. Verification and evaluation of spb deletion mutants in S. pyogenes
MGAS8232.
(A) To confirm in-frame deletions of the spbJK and spbMN operons in MGAS8232,
primers outside of the homologous recombination site were used to amplify genomic DNA
extracted from wild-type and isogenic mutants. (B) PCR products were visualized on a 1%
agarose gel stained with ethidium bromide. (C) Growth of S. pyogenes MGAS8232 and
DspbJK, DspbMN, and DspbJKMN mutants in THY at 37 °C was measured by OD600 over
the course of 18 hours. Data is presented as mean ± SD of each culture analyzed in triplicate.

52

53

in the absence of CO2, suggesting that Spb activity is CO2-dependent (Figure 7A, B).
Next, we sought to examine the effect of incubation time on bacteriocin production. To
determine the optimal incubation period, S. pyogenes strains were grown at 12-hour
intervals for up to 48 hours before simultaneous antagonism testing against M. luteus. No
differences in antimicrobial activity between incubation periods were observed, as zones
of clearance surrounding spb-producing strains were comparable to those produced after
24 hours as illustrated in Figure 7A. Lastly, to investigate the effect of different carbon
sources on Spb production, test strains were cultured on M17 agar supplemented with 0.5%
glucose under atmospheric and elevated levels of CO2. Notably, all MGAS8232 strains,
including the double bacteriocin-deficient strain, produced an inhibitory substance that was
active against M. luteus under CO2 (Figure 7C). These findings suggest Spb bacteriocin
production is induced in response to galactose and CO2, and that glucose and CO2 may
activate other unidentified bacteriocin-like inhibitory substances by S. pyogenes.

3.3 Inhibitory spectra of the Spb bacteriocins
To identify the inhibitory spectra of the Spb bacteriocins, S. pyogenes MGAS8232 wildtype and isogenic mutant strains were tested against a set of defined indictors listed in Table
1. Test strains were spotted on M17 media supplemented with 0.5% galactose and cultured
under atmospheric and elevated levels of CO2. Using the simultaneous assay, we
demonstrate that S. pyogenes strains encoding either one or both of the spb loci exhibit
antimicrobial activity against all M-types of S. pyogenes, S. dysgalactiae, and M. luteus
when grown with 5% CO2 (Table 4). In the absence of CO2, visible zones of clearance were
not observed. These results suggest that the Spb bacteriocins produced by S. pyogenes
possess a narrow range of killing that is limited to closely related bacterial species.

3.4 Time-course analysis
To examine whether microbial abundance is affected by bacteriocin production over time,
an experiment using the murine model of S. pyogenes acute nasal infection was designed
to analyze the time course of infection in the presence of the microbiota. Previous timecourse experiments utilizing this model have been performed with neomycin-treated
drinking water to reduce the microbiota to assist in the establishment of acute infection.
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Figure 7. Spb production by S. pyogenes MGAS8232 is induced by galactose and CO2.
Bioactivity assays for detecting antimicrobial activity by S. pyogenes MGAS8232 wildtype and isogenic mutant strains. (A) Cells from overnight cultures of wild-type and spbdeficient strains DspbJK, DspbMN, and DspbJKMN were spotted on M17 media
supplemented with 0.5% galactose and 0.1% CaCO3 and incubated overnight at 37 °C with
atmospheric and elevated levels of CO2. A second agar layer inoculated with M. luteus was
grown overtop, forming a confluent bacterial lawn. (B) All strains and plates were prepared
as described in Panel A. Overnight cultures of S. pyogenes were streaked across agar plates.
Cells were mechanically removed and treated with chloroform. M. luteus was streaked
perpendicular to the test strains. (C) Cells from overnight cultures of wild-type and isogenic
mutants were spotted on M17 media supplemented with 0.5% glucose and 0.1% CaCO3
and incubated for 24 hours at 37 °C under atmospheric and elevated levels of CO2.
Antimicrobial activity was tested against M. luteus.

55

56

Table 4. Antimicrobial spectra of the Spb bacteriocins.
Indicator

Elevated CO2 (5%)
MGAS8232

M. luteus
+
S. pyogenes M52
+
S. constallatus
S. uberis
S. pyogenes M4
+
L. lactis spp.
S. pyogenes M28
+
S. pyogenes M87
+
S. dysgalactiae
+
+, zone of clearance; -, no clearance zone.

DspbJK
+
+
+
+
+
+

DspbMN
+
+
+
+
+
+

DspbJKMN
+
+
+
+
+
+
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However, in the current study, neomycin was not administered to examine potential
interactions between S. pyogenes and the nasopharyngeal microbiota. HLA-DQ8
transgenic mice were intranasally inoculated with S. pyogenes MGAS8232 and sacrificed
at 24, 48, 72, and 96-hour time-points. Control mice received saline solution and were
sacrificed on day 0 for microbiome analysis. Murine cNTs were removed, homogenized
and the S. pyogenes burden in the nasopharynx was determined by growth of hemolytic
colonies on TSA with 5% sheep’s blood agar. Consistent with previous findings from our
laboratory (82), we show that mice sacrificed at the 48-hour endpoint had the highest load
of S. pyogenes in the nasopharynx (Figure 8A). By 96 hours, CFU of S. pyogenes were
dramatically reduced but not completely eliminated from the nasopharynx. However,
clearance has been shown to take up to 6 days (82). Furthermore, through the administration
of water lacking antibiotics, these data demonstrate that S. pyogenes is able to establish an
acute infection. In addition to TSA with 5% sheep’s blood agar, the endogenous murine
nasal microbiota was enumerated on various nutrient-rich mediums. The nasopharyngeal
burden recovered on TSA and BHI agar were comparable to the total bacterial counts
recovered on TSA with 5% sheep’s blood agar (Figure 8B), and therefore, not shown. Of
note, counts of total bacteria and S. pyogenes in the nasopharynx were remarkably similar,
indicating that non-streptococcal bacteria were only detected when CFU of S. pyogenes
were low. These results indicate that another approach, such as 16S small subunit ribosomal
RNA (rRNA) sequencing, may be required to identify changes in microbial diversity and
abundance in the nasopharynx in response to bacteriocin production.

3.5 Evaluation of Spb systems during nasopharyngeal
infection
Bacteriocins are considered one of the major driving forces of intraspecies bacterial
competition within a biological niche (92, 101, 154). In humans, the composition of upper
respiratory tract microbiome is particularly complex and frequently colonized by both
commensal and pathogenic bacteria, including many species of streptococci (155, 156).
Therefore, it is likely that organisms that exist within this environment produce bacteriocins
to promote colonization. To test whether the Spb bacteriocin systems play a role in the
establishment of nasopharyngeal infection by S. pyogenes, mice were infected with
MGAS8232 wild-type and the DspbJK, DspbMN, and DspbJKMN mutants. cNTs were
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Figure 8. Time-course analysis of mice infected with S. pyogenes MGAS8232.
HLA-DQ8 transgenic mice were intranasally inoculated with ~108 CFU of S. pyogenes
MGAS8232 and sacrificed at 24, 48, 72, and 96 hours post-infection. Control mice received
saline solution and were sacrificed on day 0 (n ³ 3 for each group). The nasopharyngeal
burden of (A) S. pyogenes and (B) total bacteria were enumerated at each time point. Data
points represent CFU recovered from an individual mouse. Horizontal bars represent the
median. The theoretical limit of detection (25 CFU/100 µL) is denoted by the dotted
horizontal line.
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collected at 48 hours post-infection and used to assess the bacterial burden. Mice infected
with wild-type MGAS8232 or either of the single-bacteriocin deficient mutants were able
to establish an acute infection in HLA-DQ8 mice more effectively than the doublebacteriocin knockout mutant. Overall, a significant reduction in the bacterial burden
recovered from the cNTs of DspbJKMN-treated mice was observed compared to the wildtype and the single bacteriocin-producing strains, suggesting that infection of the
nasopharynx by S. pyogenes requires at least one functional bacteriocin system (Figure 9A).
In addition, to confirm that the wild-type and mutant strains retained their antimicrobial
phenotypes, hemolytic colonies from the cNTs were cultured and spot plated onto 0.5%
GalM17 agar buffered with 0.1% CaCO3 (Figure 9B). Notably, the colonies recovered from
an in vivo environment recapitulate the in vitro phenotype of bacteriocin activity. Taken
together, these results suggest an important role for Spb bacteriocin production in
nasopharyngeal infection by S. pyogenes.

3.6 In vivo competition analyses between MGAS8232 wildtype and spb mutants
From an ecological perspective, bacteriocin production is considered an important trait in
the context of colonization and bacterial fitness (157). To explore whether wild-type S.
pyogenes could interfere with nasal infection by mutant strains of spb, a competition model
was employed in vivo. In this way, the application of the spb mutants allowed us to use
these bacteria as a proxy for competing organisms during colonization and infection. In
turn, this would give us an indication of whether the spb bacteriocin systems provide S.
pyogenes with a competitive advantage over other streptococcal strains and species. Again,
using the murine model of acute nasal infection, HLA-DQ8 transgenic mice were
inoculated with mixtures of MGAS8232 wild-type and DspbJK, DspbMN, or DspbJKMN
for a period of 48 hours. As shown in Figure 9A, when the S. pyogenes MGAS8232 wildtype, DspbJK and DspbMN strains were instilled individually, they were able to establish
infection unlike the bacteriocin-deficient strain DspbJKMN. Notably, co-inoculation
appeared to impair all spb-producing strains from establishing infection (Figure 10A).
When MGAS8232 DspbJK, DspbMN, or DspbJKMN were co-inoculated with wild-type,
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Figure 9. One functional bacteriocin system is required for efficient nasopharyngeal
infection by S. pyogenes.
Transgenic mice were intranasally infected with ~108 CFU of S. pyogenes MGAS8232
wild-type, DspbJK, DspbMN, or DspbJKMN for 48 hours (n ³ 10 per group). (A) The
nasopharyngeal burden was assessed. Each data point represents CFU from the cNT of one
mouse. Horizontal solid lines are the median of 10 independent experiments. The dotted
horizontal line is used to indicate the theoretical limit of detection (25 CFU/100 µL).
Statistical differences between groups were determined using the Mann-Whitney U test (*
P < 0.05, ** P < 0.01). (B) CFU recovered from mice were tested for bacteriocin activity
using the simultaneous antagonism assay against an M. luteus indicator lawn.
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Figure 10. Nasal coinfection with S. pyogenes MGAS8232 wild-type and spb mutants
reduces the bacterial burden in the nasopharynx but appears to promote a wild-type
dominant population.
Transgenic mice were co-inoculated in a 1:1 ratio with MGAS8232 wild-type and either of
the spb-deficient strains: DspbJK (n = 7), DspbMN (n = 6), or DspbJKMN (n = 21 without
neomycin; n = 10 with neomycin) (108 total CFU). (A) The nasopharyngeal burden was
assessed at 48 hours from 10 independent experiments. Data points represent CFU
recovered from the cNT of individual mice. The horizontal bars and dotted line represent
the median of each group and the theoretical limit of detection (25 CFU/100 µL),
respectively. (B) Colonies from wild-type (n = 395), DspbJKMN (n = 394), and coinfected
(n = 541) mice were patched on GalM17 agar supplemented with 0.1% CaCO3 and tested
for bacteriocin activity against M. luteus. Bacterial recovery from mice with CFU counts
below the limit of detection were omitted. (C) The ratio between MGAS8232 wild-type
and DspbJKMN was determined using the simultaneous antagonism assay. Clearance and
overgrowth phenotypes were quantified and used to distinguish strains. Bars represent the
mean ± SD. Significant differences were determined by the Chi-squared test (*** P <
0.001, **** P < 0.0001).
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significantly less CFU of S. pyogenes were retrieved from the mice, suggesting that
competitive interactions between the two strains were able to block infection. To evaluate
whether the presence of the spb bacteriocin systems provided a competitive advantage
during nasopharyngeal colonization, the simultaneous antagonism assay was used to
quantify the ratio of wild-type to DspbJKMN bacteria that colonized coinfected mice
(Figure 10B). Phenotypic analysis of the bacteria recovered from the coinfected mice
revealed a significantly higher rate of recovery for wild-type versus the DspbJKMN mutant
(Figure 10C). This striking difference in recovery indicates that the spbJKMN systems
gives S. pyogenes a competitive advantage against streptococcal species that may not
encode these systems.

3.7 Plasmid-based complementation of SpbMN
To further confirm that Spb is involved in establishing infection, we genetically
complemented the MGAS8232 DspbJKMN isogenic mutant using the Gram-positive/E.
coli shuttle vector pTRKL2 to generate strain MGAS8232 DspbJKMN containing
pTRKL2::PgyrA::spbMNI (Table 3), and confirmed transformation by PCR amplification
(Figure 11A). Despite successful transformation, the MGAS8232 DspbJKMN containing
pTRKL2::PgyrA::spbMNI strain did not rescue the antimicrobial phenotype in vitro (data
not shown). Although antimicrobial activity was not restored to the double-bacteriocin
deficient strain in vitro, we utilized the complement strain in our acute infection model
using HLA-DQ8 transgenic mice. Consistent with our in vitro data, MGAS8232
DspbJKMN containing pTRKL2::PgyrA::spbMNI proved to be ineffective at restoring
antimicrobial activity following murine nasopharyngeal passage. It is important to note that
although there was no statistical difference between the bacterial burden in mice infected
with

the

S.

pyogenes

MGAS8232

DspbJKMN

and

DspbJKMN

containing

pTRKL2::PgyrA::spbMNI strains, there was a trend towards higher CFU recovery in the
DspbJKMN + pTRKL2::PgyrA::spbMNI-treated group compared to the non-complemented
mutant (Figure 11B). It also appears as though many of the colonies recovered from murine
cNTs were found to be sensitive to erythromycin, indicating that the plasmid may have
been lost during infection (Figure 11C). Based on these findings, plasmid-based
complementation may be effective at restoring the colonization phenotype, but due to the

66

Figure 11. Plasmid-based complementation of SpbMN in S. pyogenes MGAS8232
DspbJKMN does not increase the bacterial burden in the nasopharynx or restore

antimicrobial activity.
(A) Integration of the pTRKL2 plasmid containing spbMNI under control of the gyrA
promoter into S. pyogenes MGAS8232 DspbJKMN. Genomic DNA was amplified via PCR
and visualized on a 1% agarose gel. (B) Transgenic mice were intranasally infected with
108 CFU of either S. pyogenes MGAS8232 DspbJKMN or MGAS8232 DspbJKMN
containing pTRKL2::PgyrA::spbMNI. The nasopharyngeal burden was assessed from
murine cNTs 48 hours post-infection. Data points represent CFU of individual mice.
Horizontal bars represent the median. The horizontal dotted line indicates the theoretical
limit of detection (25 CFU/100 µL). Significance determined by Mann-Whitney U test (ns,
not significant). (C). Colonies recovered from murine cNTs were tested for bacteriocin
activity against M. luteus using the simultaneous antagonism assay on GalM17 agar
supplemented with 0.1% CaCO3 and erythromycin.
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high rate of excision throughout the length of infection, this approach could not reliably
restore the wild-type phenotype. Together this suggests that an alternative method to
plasmid complementation for spbJKMN should be explored to fully validate the role of
these bacteriocins in establishing infection by S. pyogenes.

3.8 In vitro and in vivo detection of spb expression
Recent findings from our laboratory have demonstrated that transcription of spbM is highly
upregulated at 48 hours following infection in the mouse nasopharynx. In comparison,
spbM transcripts were hardly detectable in vitro. This suggests that bacteriocin-encoding
genes are transcribed in an in vivo environment, where bacteriocin production may be
advantageous for mediating competition against other bacteria (100). Because GAS
infection of the nasopharynx is capable of inducing spbM expression, we examined whether
infection would increase other spb transcripts similarly. Using qRT-PCR, speC, spbJ, spbK
and spbM transcripts were analyzed from wild-type S. pyogenes MGAS8232 grown under
in vitro (OD600 ~0.2 or ~0.8) and in vivo (following 48-hour infection) conditions. All data
were normalized to internal housekeeping gene gyrA, and expression fold changes were
determined using the 2-DDCt method (158). The speC gene was used as a positive control. In
this study, we demonstrate that spbM transcription is 8-fold greater in vivo compared to
wild-type MGAS8232 grown at early and late exponential phase. These findings support
previous data reported from our laboratory (100). Similarly, expression of spbJ and spbK
genes were upregulated under in vivo growth conditions. Notably, spbJ transcripts were
significantly increased in the nasopharynx, with a 2000- and 500-fold difference in gene
expression relative to early and late in vitro conditions, respectively (Figure 12). These
findings provide strong evidence to suggest that the spb genes are specifically induced in
an in vivo nasopharyngeal environment.
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Figure 12. Transcription of bacteriocin-encoding genes are upregulated in vivo during
nasopharyngeal infection.
Expression analyses of spb bacteriocin-encoding genes. Total RNA was isolated from
cultures of S. pyogenes MGAS8232 grown to OD600 ~0.2 or ~0.8 (early and late in vitro
conditions, respectively; n = 4) and from HLA-DQ8 mice intranasally infected with
MGAS8232 for 48 hours (n = 2; in vivo conditions). Transcription levels of speC (positive
control), spbJ, spbK, and spbM were determined by SYBR green qRT-PCR and normalized
to the housekeeping gene gyrA. Data are presented as fold change from wild-type in vivo
relative to in vitro growth conditions. Data represent the mean of four independent
experiments with samples analyzed in duplicates.
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4.1 Discussion
S. pyogenes is a globally prominent bacterial pathogen with the propensity to colonize the
skin and upper respiratory tract of a human host (1, 23). Successful adaptation to different
tissues is, in part, due to S. pyogenes’ ability to sense variations in the external environment
and rapidly alter its gene expression profile. Due to S. pyogenes’ remarkable versatility,
ongoing research efforts are focused on identifying the spatial and temporal patterns of
regulation that control virulence factor gene expression and immune-evasion mechanisms
utilized by S. pyogenes to establish infection (110, 131, 132, 137). In comparison, the
processes governing ecological stability, bacterial fitness, and competition against the
microbiota, which are vital for colonization, remain poorly understood.
Microbial communities within humans are often characterized as competitive and complex
environments that play an important role in determining health and disease. Resident
microbiota are involved in many human biological processes, including modulation of the
immune system, metabolism, epithelial development, as well as the prevention of
colonization by opportunistic pathogens (159, 160). In any given biological niche,
competition between microorganisms is driven by the need to acquire finite resources such
as space and nutrients. In order to meet these demands, bacteria have adapted evolutionary
traits and tools (i.e., degradative enzymes, bacteriocins and antimicrobial compounds, and
mechanisms to disrupt quorum sensing-mediated signalling) to compete with one another
(159, 161).
Opportunistic pathogens such as streptococci must compete with a variety of pre-existing
bacteria to colonize the upper respiratory tract of humans. In many cases, direct interactions
between bacteria of the same or closely related species are mediated through the production
of bacteriocins (101, 159, 162); a mechanism widely used by streptococci. For example,
bacteriocins salivaricin (Sal) A and SalB produced by S. salivarius – a well-characterized
colonizer of the oral cavity – are able to inhibit growth of pathogenic streptococci, including
S. pyogenes (163, 164). However, bacteriocins are not exclusively produced by commensal
bacteria. Invaders of the upper respiratory tract and the oral cavity, such as S. pneumoniae
and Streptococcus mutants, also utilize bacteriocins to mediate intraspecies competition
(92, 101, 161, 162). While these groups have all demonstrated an improved ability to
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colonize when compared to their bacteriocin-deficient counterparts, S. pyogenes also
encodes a number of bacteriocin genes that have received little recognition. In this study,
we demonstrate that S. pyogenes utilizes two novel class IIb bacteriocin systems to establish
infection and strain dominance within the polymicrobial environment of the mouse
nasopharynx.
Recently published findings from our laboratory have identified and characterized a novel
two-component class IIb bacteriocin in S. pyogenes, which has been designated as the
spbMN locus (100). Based on unpublished data, S. pyogenes appears to encode a second
proximal type IIb system with potential genetic redundancy to spbMN. In turn, we
designated these open reading frames as the spbJ and spbK genes. To characterize SpbJK
and SpbMN in terms of their inhibitory spectrum, multiple approaches, including
recombinant peptide expression and bioactivity testing, have been utilized. Using
recombinant expression of SpbM and SpbN, a number of different streptococcal species,
including S. pyogenes, S. dysgalactiae, S. uberis, as well as other Gram-positive bacteria
such as M. luteus and L. lactis were shown to be susceptible to antimicrobial activity (100).
To determine the range of SpbJ and SpbK activity, a similar approach was attempted;
however, because SpbK appears to be toxic in E. coli, recombinant peptide expression
proved to be less feasible. A goal of this project was thus to determine the regulatory cues
required to induce expression of spb in vitro. This would allow us to test for antimicrobial
activity using the standard simultaneous and deferred antagonism assays. Through
empirical analysis, we show that spb-mediated inhibition is induced in response to
galactose and CO2. To formally demonstrate that the spb operons are functionally active in
S. pyogenes, the double-bacteriocin knockout strain was also screened for antimicrobial
activity. Under the same conditions, we show that the DspbJKMN strain is unable to inhibit
grown of the Spb-sensitive indicator M. luteus (Figure 7A, B). Since most bacteriocins have
a narrow range of killing, it is widely thought that they play a role in mediating intraspecies
competition (157, 162). To investigate this assumption, we tested the wild-type and
isogenic mutant strains of MGAS8232 for bacteriocin production against a defined set of
nine indicator strains listed in Table 1. Although there was significant variability between
experiments, the putative inhibitory spectrums have been reported in Table 4. We speculate
that SpbJK and SpbMN are active against several S. pyogenes serotypes, including M52,
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M4, M28, M87 strains, M. luteus and S. dysgalactiae, and that the Spb systems possess a
similar inhibitory range. Interestingly, both susceptibility testing methods have reported
slightly different antimicrobial targets. We predict that the observed disparities are due to
differences in protein expression levels. Based on these findings, further testing is required
to determine the range of targets susceptible to SpbJK and SpbMN. Moreover, it would be
of interest to identify the antimicrobial compound that is activated in response to glucose
and CO2 (Figure 7C).
It is possible that other regulatory signals may also induce expression of spb by S. pyogenes.
It has been recently reported that in the M179 serotype S. pyogenes strain JS12, bacteriocin
production is stimulated through a series of sequential events involving the sil locus. In this
strain, which contains a fully intact sil, host cell membrane-triggered stress caused by the
delivery of SLS and SLO is able to upregulate asparagine synthesis (137, 138). Asparagine
appears to mediate activation of sil in a SilCR-dependent manner, which upregulates
bacteriocin production (138). This proposed mechanism for Spb regulation and transport is
possible in strains encoding an intact sil locus; however, it is currently unknown what
replaces sil function in S. pyogenes strains with mutations in this operon, such as
MGAS8232 (i.e., truncation in silD). This is a major question that has yet to be answered,
but our work demonstrates that additional pathways independent of sil are capable of
inducing spb expression. Based on the regulatory cues we have identified in this study, we
predict that multiple regulators may be involved in transcriptional regulation of spb,
including CovRS, Mga, CcpA, and LacD.1. These genes were chosen as putative regulators
for their role in virulence factor gene expression, sugar metabolism, or in terms of their
activation signals, which correspond with the regulatory cues required to induce spb. To
test the possible involvement of these genes in spb regulation, we intend to generate
deletions in each of these genes (refer to Figure 4); at this time, only the plasmid-based
deletion constructs have been generated (Table 3). In addition, ongoing experiments in our
laboratory are focused on elucidating the potential regulators and transporters involved in
Spb production through transposon-mediated random mutagenesis. This involves the
development of a transposon mutant library in MGAS8232 using the kanamycin-resistant
in vivo delivery plasmid pKRMIT (165).
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Asymptomatic carriers of S. pyogenes are typically infected with one strain which persists
in the nasopharynx for an extended period of time. In some cases, the bacteria are passively
cleared, or in others, replaced by another GAS strain. Although serotype switching is a
common phenomenon among group A and group B streptococci, the mechanisms which
determine strain dominance remain unclear (12, 166). One likely mechanism used to
explain these patterns of colonization are bacteriocins. In this study, we demonstrate that
expression of one functional Spb system is required to establish acute infection in our
transgenic mouse model. Loss of either SpbJK or SpbMN did not impair nasopharyngeal
infection (Figure 9A) or ablate antimicrobial activity (Figure 9B). This is not surprising
because we believe that these systems are redundant and used to mediate competition in
the nasopharynx similar to other streptococci. In contrast, the bacteriocin-deficient strain
DspbJKMN failed to establish infection consistently in the mice. Inoculation with
DspbJKMN elicited a bimodal phenotype, by which only a fraction of mice had a
nasopharyngeal burden similar to that of wild-type (Figure 9A). These findings suggest that
in some cases, host factors such as the composition of the microbiota in the nasopharynx,
allow the bacteria to establish an infection. However, a significant decrease in the bacterial
burden recovered from murine cNTs indicates that deletion of both spb operons reduces the
fitness of S. pyogenes in a polymicrobial environment.
Bacteriocins play a crucial role in altering the composition of the microbiota in humans. In
a particular niche, such as the gastrointestinal tract, they are able to modulate the
microenvironment in ways that are advantageous or determinantal to certain groups of
bacteria (167). To examine differences in microbial abundance and diversity due to Spb
production in the nasopharynx, an in vivo time course analysis of wild-type S. pyogenes in
the presence of the background microbiota was performed. Our analysis was limited to the
identification of different bacteria by plating on nutrient-rich mediums, which proved not
to be feasible. This is because differences in bacterial counts of S. pyogenes and total
bacteria recovered from murine cNTs were very similar (Figure 8A, B), and did not provide
the means to comprehensively evaluate all bacterial species colonizing the nasopharynx,
including those that are unculturable in the laboratory. Therefore, it would be of interest to
assess how infection by S. pyogenes may change the microbial composition in the
nasopharynx overtime using a more reliable approach such as 16S rRNA gene sequencing.
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Although there may be limitations to the approach we have utilized, our data has revealed
an important finding. When S. pyogenes is able to establish infection, as observed by high
bacterial loads, it appears as though no other bacteria were able to colonize the mice. This
finding suggests that the establishment of S. pyogenes in a niche may preclude other
bacteria from colonizing. However, it is important to note that although this mouse model
is used to mimic acute nasopharyngeal infection, microbial population dynamics differ
substantially in humans. Therefore, it may be advantageous to collect nasopharyngeal wash
samples from individuals colonized with S. pyogenes, and process these samples using 16S
rRNA sequencing. This approach has been previously utilized to characterize changes in
the nasopharyngeal composition that contribute to asthma (168), and may provide
important insights on population dynamics during S. pyogenes infection in humans.
The BlpM and BlpN peptides produced by S. pneumoniae, which are known homologs of
SpbM and SpbN (100), have also been studied in the context of colonization. Interestingly,
in S. pneumoniae, previous work by Dawid et al. has shown that mutations in the blp operon
do not impair nasopharyngeal infection when the mutant strain was instilled individually.
However, when wild-type and blp-deficient strains were co-inoculated in equal numbers,
the parent strain was able to outcompete the mutant, indicating that Blp production could
interfere with colonization of blp-negative strains (101). In contrast, we have shown that
co-inoculation impairs all spb-producing strains from establishing infection (Figure 10A).
These results were highly unexpected and may suggest a less prominent role for Spb in
mediating microbial interactions and a more important role in mediating GAS adherence
compared to Blp. Although there is no exact mechanism to explain this phenomenon, one
study has reported a similar finding. In a study by Lee et al., interactions between the gut
microbiota and Bacteroides fragilis were examined using a germ-free murine model of gut
colonization. They demonstrated that mice infected with one B. fragilis strain were resistant
to subsequent colonization by another strain of the same species. Remarkably, however,
when mice were infected with B. fragilis and challenged with another Bacteroides species,
both able to efficiently colonize. These results suggest that certain bacteria colonize the gut
by saturating a specific and limited niche to effectively exclude similar strains from
establishing colonization. This observation of colonization resistance, which they have
coined as the “saturable niche hypothesis”, is used to describe how two closely related

77

bacteria may only co-exist if they have their own particular niches (169). Based on these
findings, we may speculate that individual S. pyogenes strains may colonize the
nasopharynx in a similar species-specific and saturable manner. In the current study, our
mice were challenged with two S. pyogenes strains at the same time; both of which would
theoretically occupy the same niche. Therefore, we can presume that neither strain was able
to effectively displace the other to establish infection. In cases where the nasopharyngeal
burden is high, we predict that S. pyogenes wild-type was able to exclude the DspbJKMN
strain and infect the mice (Figure 10A). To support this notion, we show that more than
75% of colonies retrieved from coinfected mice have antimicrobial activity against M.
luteus (Figure 10B, C). Thus, these results suggest that expression of spb may be critical
for the establishment of nasopharyngeal infection and dominance in the host.
We next investigated whether complementation in trans could restore the ability of the
bacteriocin-deficient strain to establish nasopharyngeal infection. Despite successful
transformation of the spbMNI genes into MGAS8232 DspbJKMN (Figure 11A), this strain
was unable to restore colonization in transgenic mice. There was no significant difference
between the bacterial burden of mice infected with DspbJKMN containing
pTRKL2::PgyrA::spbMNI compared to DspbJKMN; however, an increased trend in CFU
was observed (Figure 11B). Furthermore, it appears as though many of the colonies
recovered for antimicrobial testing against M. luteus were sensitive to erythromycin,
indicating that the plasmid may have been lost during infection (Figure 11C). Therefore,
colonization defects of DspbJKMN could not be restored through plasmid-based
complementation. Future work will aim to complement S. pyogenes MGAS8232
DspbJKMN with spbJKL or spbMNI in cis to rescue the infection and antimicrobial
phenotypes.
Analysis of the Spb systems using qRT-PCR demonstrates that spbJ, spbK, and spbM
expression are highly upregulated in vivo compared to in vitro growth conditions. This data,
which is similar to previous findings from our laboratory (100), further supports the idea
that these bacteriocins are important for mediating competition within a polymicrobial
environment of the nasopharynx (100). Interestingly, with regard to spbJK expression, our
preliminary data seems to suggest that the a and b-encoding genes are not transcribed in a
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1:1 ratio. While they may be released in equal amounts for optimal activity, these findings
suggest that the SpbK structural peptide is sequestered and/or degraded compared to SpbJ.
To our knowledge, this is first instance which may suggest that bacteriocins of the same
class IIb system could be transcriptionally regulated in a different manner. However, a more
likely explanation for this phenomenon involves the immunity protein. In lantibiotics, such
as nisin, the immunity protein is involved in sequestering the bacteriocin on the cell
membrane (170, 171). The likely immunity protein for SpbJK, which encodes a putative
membrane-bound metalloprotease, may also sequester SpbK in a similar mechanism to
nisin. However, it is also possible that SpbL may directly degrade excess SpbK, similar to
the metalloprotease immunity protein identified in Enterococcus faecalis (170, 172).
Although it is not certain why spbK is transcribed in a greater quantity, these data provide
strong evidence to suggest that S. pyogenes utilizes SpbJK and SpbMN bacteriocins to
colonize the host.
Host genetic factors and the composition of the microbiota contribute to a predisposition
for developing S. pyogenes infection. In this work, we provide strong evidence that
demonstrates that antimicrobial products, SpbJK and SpbMN, are critical for establishing
infection in the nasopharynx. Although the mechanism has yet to be elucidated, our
findings suggest that S. pyogenes produces bacteriocins to challenge closely related
competitors. If this bacterium is successful, it may be able to saturate the nasopharyngeal
niche. Our expression analyses further validate this hypothesis and show that Spb is
produced only under in vivo growth conditions that are used to mimic a competitive
microbial environment. In summary, our study has identified and characterized two novel
class IIb bacteriocins that are used by S. pyogenes to establish infection and strain
dominance in a host.
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